Study Title: 
Sponsor: 
IND Number: 
EudraCT Number: 
Clinical Trial s.gov 
Identifier: 
Indication: 
Protocol ID: (rJ GILEAU 
CLINICAL STUDY PROTO COL 
A Phase 2, Multicenter, Ope n-Label Study to Eval uate the 
Efficacy and Safety of Ledipasvir/Sofo sbuvir in Subjects with 
Genotype 1, 4, 5 and 6 Ch ronic HCV Infectio n Who are on 
Dialysis for End Stage Renal Disease 
Gilead Sciences, Inc. 
333 Lakeside Drive 
Foster City, CA 94404 
115268 
2016 -003489 -25 
[STUDY_ID_REMOVED] 
Hepatiti s C V ims Infection 
GS-US-337- 4063 
Gilead Study Director: Name: IPIPD 
IPIPD 
IPIPD 
PPU Telephone: 
Fax: 
Email address: 
Gilead Medical Monitor: Name: 
Telephone: 
Fax: 
Email address: 
Protocol Version/Date: Original: 
Ame ndm ent 1.0: 
Ame ndm ent 2.0: 
Ame ndm ent 3.0: IPIPD 
IPIPD 
IPIPD 
PPU 
23 Septe mber 2016 
29 Nove mber 2016 
30 Janmuy20 17 
02 Marc h 2017 
CONFIDE NTIALITY STATEME NT 
The info1mation contained in this document, paiiic ularly unpublished data, is the prope 1iy or 
under control of G ilead Sciences, Inc., and is prov ided to you in confidence as an investigato r, 
potential investigato r, or consultant, for review by you, your staff, and an applicable Institutional 
Review Board or Independent Ethics Committ ee. The infonnatio n is o nly to be used by you in 
connectio n with author ized clinical studies of the investigational dmg descr ibed in the protocol. 
You will not disclose any of the infonnation to others without written a uthorizatio n from 
Gilead Sciences, Inc., except to the extent necessa1 y to obtain infonned consent from those 
perso ns to whom the dmg m ay be admini stered. 
LDV/ SOF 
Protocol GS-US-337-4063 
Gilead Sciences, Inc. Final 
Amendment 3.0 
TABLE OF CONTE NTS 
TABLE OF CONTENTS ........................ ....... ................... ................... ................................. ..................... ............. ...... 2 
LIST OF IN-TEXT TABLES ................... ................... ................................. ..................... .......................... .................. 5 
LIST OF IN-TEXT FIGURES ................. .............. ....................................... ................................. .............. ................. 5 
PROTOCOL SYNOPSIS ........................ ....... ................... ................... ................................. ..................... ................... 6 
GLOSSARY OF ABBREVIATIO NS AND DEFINITIO N OF TERMS .................. .................... ........ .............. ........ 11 
1. INTRODUCTION .......................... ............ .............. ................... ...................................................... ................. 15 
1.1. Background ........................ .......................... ................... ................................. ..................... ................. 15 
1.2. Ledipa svir/Sofosbuvir Fixed Dose Combination .................. ................... ................................. ............. 16 
1.2.1. General Info1mation ................... ................... ................................. ..................... ................. 16 
1.2.2. Additional Clinical Infonnation; Study GS-US-334 -0154 .......................... ............ ............. 16 
1.2.3. Additional Non-Clinical Toxicology Infoimation ....................... ....... ................... ............... 21 
1.3. Rationale for This Study ............................ .......................... .................................................................. 21 
1.4. Rationale for Dose Selection ofLDV /SOF .......................... ............ .............. ................... ..................... 22 
1.5. Risk/BenefitAssess1nent for the Study ............................... .......................... ............ .............. ............... 23 
1.6. Compliance ........................ ....... ................... ................... ................................. ..................... ............. .... 24 
2. OBJECTIVES .......................................................... ............ .............. ................... .............................................. 25 
3. STUDY DES IGN ........................... ........................... .......................... ................. .............................. ................. 26 
3.1. 
3.2. 
3.3. 
3.4. 
3.5. 3.6. 
3.7. Study Design ...................... ...........
......................................................................................... ............ .... 26 
Visit Schedule ..................... ................... ..................... .. ............................... .......................... ....... ......... 26 
Dw·ation ofTreatinent .......................................................... ............ .............. ................... ..................... 26 
Stopping Rules and Discontinuation Criteria ....................... ....... ................... .............. .......................... 27 
3 .4.1. Toxicity -Based Stopping Criteria ....................... ....... ................... .............. .......................... 27 
3.4.2 . Virologic Response Base Stopping Criteria ............................... .......................... ............ .... 28 
HIV Virolo ic Rebound Criteria .................. ................... ................................. ..................... ............. .... 28 
. ......................................................................................... ............ .... 30 
. ............... ............... .. .............................. .......................... ............ .... 30 
............................... .......................... ............ .............. ............... 30 
Bio1narker Testing ................ ............... .. .............................. .......................... ............ .............. ............... 30 
3.7.1 . Sain les for O tional Future Research .......... .................... .................... .......................... ..... 30 
3.7.2 . .. ................................................... 31 
4. SUBJECT POPULATION ................ ............... .. .............................. .......................... ............ .............. ............... 32 
4.1. Inclusion Criteria ................. .............. ....................................... ................................. .............. ............... 32 
4.2. Exclusion Criteria ............................................................... ........................... ............ .............. ............... 33 
5. INVESTIGATIONAL MEDICINAL PRODUCTS ......................... ............ .............. ................... ..................... 36 
5.1. Randomization , Blinding and Treatment Codes ................... ................... ................................. ............. 36 
5.2. Description and Handling ofLDV/SOF FDC ........ .................................. .................... .................... ...... 36 
5.2.1 . Fonnulation .............................. .......................... ....... ................... ................... ..................... 36 
5.2.2 . Packaging and Labeling .............. ............................................... .......................... ....... ......... 36 
5.2.3 . Storage and Handling ................. .............. ....................................... ................................. .... 36 
5.3. Dosage and Administration ofLDV /SOF FDC .................... ................... .............................................. 37 
5 .4. Prior and Concoinitant Medications .............. ............................................... .......................... ....... ......... 3 7 
5.5. Accountability for LDV /SOF FDC ............... .............. .. ............................... .......................... ....... ......... 38 
5.5.1 . Investigational Medicinal Product Retwn or Disposal .............................. .......................... 39 
6. STUDY PROCED URES ................. .............. ....................................... ................................. .............. ............... 40 
CONF IDENTIAL Page2 02 March 2017 
LDV /SOF 
Protocol GS-US-337-4063 
Gilead Sciences, Inc. Final 
Amendment 3.0 
6.1. Subject Enrollment and Treatment Assignment.. .................. ................... .............................................. 40 
6.1.1. Pretreatmen t Assess1nent s ...................................... ................................. .............. ............... 40 
6.2. Day I Assessment s ............... .............. .. ............................... .......................... ....... ................... ............... 42 
6. 3. T reatinen t Assessment s .............................. .......................... ....... ................... ................... ..................... 43 
6.3.1. Week 2 (± 3 days): Group I, 2, and 3 .......... .............. .......................... .................... ............ 43 
6.3.2 . Week 4 (± 3 days): Group I, 2, and 3 .......... .............. .......................... .................... ............ 44 
6.3.3 . Week 6 (± 3 days): Group I, 2, and 3 .......... .............. .......................... .................... ............ 45 
6.3.4 . Week 8 (± 3 days): Group 2 and 3 (For Group I Week 8, see End of 
Treatment Visit) ........................ ....... ................... ................... ................................. ............. 45 
6.3.5 . Week 12, 16, and 20 (± 3 days): Group 3 (For Group 2 Week 12, see End 
of Treatment Visit) ..................... ................... ..................... .. ............................... ................. 46 
6.3.6 . End of Treatmen t Visit: Group I Week 8 (± 3 days), Group 2 Week 12 
(± 3 days) , Group 3 Week 24 (± 3 days) or Early Te1mination (ET) ................................... 47 
6.4. Post-ti·eatment Assessmen ts ........................ ....... ................... ................... ................................. ............. 48 
6.4.1. Postt1·eatment Week 4 Visit(± 5 days): Group I, Group 2, and Group 3 ........ .............. ....... 48 
6.4.2 . Postt1·eatment Week 12 Visit (± 5 days): Group I, Group 2 and Group 3 ............ ........ ....... 49 
6.4.3 . Postt1·eatmen t Week 24 Visit (±5 Days): Only for Subject s who Achie ved 
SVRl2 ................ ............... .. .............................. .......................... ............ .............. ............... 49 
6.5. Early Te1mination (ET) .............................. .......................... ....... ................... ................... ..................... 50 
6.6. Unscheduled Visit ................ ............... .. .............................. .......................... ............ .............. ............... 50 
6.7. End ofStudy ....................... ....... ................................. ....................................... ..................... ............ .... 50 
6.8. Post Study Care ................... ................... ................................. ..................... .......................... ................ 50 
6.9. Procedw·e s and Specifications ................................................ ............... .. .............................. ................. 50 
6.9.1 . Clinica l Laborato1y Analytes ............................ .......................... ......................................... 50 
6.9.2 . Medical Histo1y ......................... ............ .............. ................... ................................. ............. 51 
6.9.3 . Comp lete Physical Examination ......................... ............ .............. ................... ..................... 51 
6.9.4 . Heigh t & Weight Measw·e1nent. ......................... ............ .............. ................... ..................... 52 
6.9.5 . Vita.I Signs ............................... ........................... ............ .............. ................... ..................... 52 
6.9.6 . Body Mass Index (BMI) .............. ............................................... .......................... ....... ......... 52 
6.9.7 . 12- LeadECG ........................... ............. ........................................ ............... .. ...................... 52 
6.9.8 . Heal th Related Quality of Life (HRQoL ) ............ ........ .................. ........ .......................... ..... 52 
6.9.9 . Viral Sequencing/Phenotyping (Archi ve) ...................................... ..................... ............. .... 53 
6.9.10. S arsePKSam le ................................................ ............... .. .............................. ................. 53 
6.9.11. .. .............. ............... .. .............................. .......................... ............ .... 53 
6.9.12. .. ............................. .......................... ............ .............. ............... 53 
6.9.13. P a1macogeno1ruc s Testmg ............................... .......................... ............ .............. ............... 54 
6.9.14. Archi ve sainple .......................... ............ .............. ................... .............................................. 54 
6.9.15. Pregnancy Testing ................................................ ............... .. .............................. ................. 54 
7. ADVERSE EVENTS AND TOXIC ITY MANAGEME NT ........ .............. .......................... .......................... ..... 55 
7. I. Definitions of Adverse Ev ents, Adverse Reac tions, and Seriou s Adverse Events ................................. 55 
7.1.1. AdverseEvents .......................... ............ .............. ................... .............................................. 55 
7.1.2. Serious Adverse Events ............... .............. .. ............................... .......................... ....... ......... 55 
7.1.3. Clinica l Laborato1y Abno1malitie s and Other Abno1mal Assessmen ts as 
Adverse Ev ents or Serious Adverse Events .. ...................... .......................... .................. ..... 56 
7 .1.4. Assessment of Causality for Study Thugs and Procedures .......................... ............ ............. 56 
7.1.5. Assessment of Severity ............... .............. .. ............................... .......................... ....... ......... 57 
7 .2. Investigator Requiremen ts and Instiuctions for Repo1ting Adverse Ev ents and Seriou s 
Adverse Ev ents to Gilead ........................... ............. ........................................ ............... .. ...................... 57 
7 .2.1. Requiremen ts for collection prior to study dmg initiation: .................. .................... ............ 57 
7.2.2. Adverse Ev ents .......................... ............ .............. ................... .............................................. 57 
7.2.3. Serious Adverse Events ............... .............. .. ............................... .......................... ....... ......... 57 
7.2.4. Electi·onic Seriou s Adverse Event (eSAE) Repo1ting Proce ss .............. .......................... ..... 58 
7 .3. Gilead Repo1ting Re.quirement s ................... ................... ................................. ..................... ................. 58 
CONF IDENTIAL Page3 02 March 2017 
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 4 02March 2017Toxicity Management ............................................................................................................................ 59 7.4.
7.4.1. Subject Stopping Rules ........................................................................................................ 59
Special Situations Reports ...................................................................................................................... 59 7.5.
7.5.1. Definitions of Special Situations .......................................................................................... 59
7.5.2. Instructions for Reporting Special Situations ....................................................................... 60
8. STATISTICAL CONSIDER ATIONS ................................................................................................................ 62
Analysis Objectives and Endpoints ........................................................................................................ 62 8.1.
8.1.1. Analysis Objectives .............................................................................................................. 62
8.1.2. Primary Endpoint ................................................................................................................. 62
8.1.3. Secondary Endpoint ............................................................................................................. 63
8.1.4. Other Endpoints of Interest .................................................................................................. 63
Analysis Conventions ............................................................................................................................. 63 8.2.
8.2.1. Analysis Sets ........................................................................................................................ 63
Data Handling Conventions ................................................................................................................... 64 8.3.
Dem ographic Data and Baseline Characteristics ................................................................................... 66 8.4.
Efficacy Analysis ................................................................................................................................... 66 8.5.
8.5.1. Primary Analysis .................................................................................................................. 66
8.5.2. Secondary Analyses ............................................................................................................. 66
Safety Analysis ....................................................................................................................................... 66 8.6.
8.6.1. Extent of Exposure ............................................................................................................... 66
8.6.2. Adverse Events ................................................................ ................................ ..................... 67
8.6.3. Laboratory Evaluations ........................................................................................................ 67
Other Safety Evaluations ........................................................................................................................ 68 8.7.
Pharmacokinetic Analysis ...................................................................................................................... 68 8.8.
Sample Size ............................................................................................................................................ 68 8.9.
Data Monitoring Committee .................................................................................................................. 68 8.10.
9. RESPONSIBILITIES .......................................................................................................................................... 69
Investigator Responsibilities .................................................................................................................. 69 9.1.
9.1.1. Good Clinical Practice .......................................................................................................... 69
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee 
(IECRevie w and Appr oval................................................................................................... 69
9.1.3. Informed Consent ................................................................................................................. 69
9.1.4. Confidentiality ...................................................................................................................... 70
9.1.5. Study Files and Retention of Records .................................................................................. 70
9.1.6. Case Report Forms ............................................................................................................... 71
9.1.7. Investigational Medicinal Product Accountability and Return ............................................. 72
9.1.8. Inspections ............................................................................................................................ 72
9.1.9. Protocol Compliance ............................................................................................................ 72
Sponsor Responsibilities ........................................................................................................................ 73 9.2.
9.2.1. Protocol Modifications ......................................................................................................... 73
9.2.2. Study Report and Publications ............................................................................................. 73
Joint Investiga tor/Sponsor Responsibilities ........................................................................................... 73 9.3.
9.3.1. Payment Reporting ............................................................................................................... 73
9.3.2. Access to Information for Monitoring .................................................................................. 74
9.3.3. Access to Information for Auditing or Inspections .............................................................. 74
9.3.4. Study Discontinuation .......................................................................................................... 74
10. REFERENCES ................................................................................................................................................... 75
11. APPENDICES .................................................................................................................................................... 77
Appendix 1. Investigator Signature Page .................................................................................................... 78
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 5 02March 2017Appendix 2. Study Procedures Table .......................................................................................................... 79
Appendix 3. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities ............... 85
Appendix 4. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................. 107
Appendix 5. Opportunistic Infections ....................................................................................................... 110
LIST OF IN -TEXT TABLES
Table 5-1. Disallowed and Concomitant Medications to be Used w ith Caution ..................................... 38
LIST OF IN -TEXT FIGURES
Figure 3-1. HIV Virologic Rebound Schema ............................................................................................ 29
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 6 02March 2017PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Study Title : A Phase 2, Multicenter, Open -Label Study  to Evaluate the Efficacy  
and Safet y of Ledipasvir/Sofosbuvir in Subjects with 
Genoty pe1, 4, 5 and 6 Chronic HCV Infection Who are on Dial ysis 
for End Stage Renal Disease
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:115268
2016-003489-25
[STUDY_ID_REMOVED]
Study Centers Planned: Approximately  35centers in , North America , Europe ,and Asia 
Pacific
Objectives: The primary  objective sof this study  areas follows:
To evaluate the antiviral efficacy  of treatment with 
ledipasvir/sofosbuvir ( LDV/ SOF) for 8, 12,or 24 weeks in 
subjects with chronic hepatitis C virus (HCV) infection who are 
on dialy sis for End Stage Renal 
Disease (ESRD ),as measured b y 
the proportion of subjects with sustained viral response 12 weeks 
after cessation of treatment (SVR12)
To evaluate the safet y and tolerability  of each treatment regimen
The secondary  objectives of this study  are as follows: 
To determine the proportion of subje cts who attain SVR at 4 and 
24weeks after cessation of each stud y treatment regimen (SVR4 
and SVR24)
To evaluate the proportion of subjects with virologic failure
To evaluate the kinetics of circulating HCV RNA during 
treatment and after cessation of treatment
To evaluate the emergence of viral resistance to LDV and SOF
during treatment and after cessation of treatment
To evaluate the stead y-state pharmacokinetics of LDV and SOF 
and its metabolites in subjects who are on dial ysis for (ESRD )
LDV/SOF 
Protocol GS-US-337 -4063 
Gilead Sciences , Inc. 
Study Design: 
Substudies 
CONFIDENTIAL The explorato 1 y objectives of this study are: Final 
Amendment 3.0 
Approx imately 100 subjects with genotype 1, 4, 5, or 6 HCV 
infection will be emolled to 1 of 3 groups and will receive treat ment 
with LDV/SOF for 8, 12, or 24 weeks. The treatment group to which 
subjects are assigned will be detennined by genotype , the absence or 
presence of ciIThosis and wh ether the subj ect is treatment na'ive or 
treat ment expe rienced. 
Group 1: Treatment na'ive genotype 1 subjects without c inhosis 
will be treated with LDV/ SOF for 8 weeks 
Group 2: Treatment exper ienced genotype 1 subjects and t reatment 
na'ive or treatment exper ienced genotype 4, 5, and 6 
subjects without ciIThosis will be treated with L DV /SOF 
for 12 weeks 
Group 3: Subjects with compensated cinhosis will be treated with 
LDV / SOF for 24 weeks 
Page 7 02 March 2017 
LDV/SOF 
Protocol GS-US-337 -4063 
Gilead Sciences , Inc. 
Number of Subjects 
Planned: 
Target Population: 
Duration of 
Treatme nt: 
Diagnos is and Main 
Eligibility Criteria: 
Study Proced ures/ 
Freque ncy: 
CONFIDENTIAL Approximately 100 subjects Final 
Amendment 3.0 
Adults with chronic hepatitis C vims (H CV) infect ion who are on 
dialysis for ESRD 
Subj ects will be treated for 8, 12, or 24 weeks. 
Chronic HCV infec ted genotype 1, 4, 5, or 6 male and non-pregna nt/ 
non-lactat ing female su bjects aged 18 years or older who are on 
dialysis for ESRD, including subjects with HIV co-infec tion if they 
are suppressed on a stable , protoco l-approved antiretroviral (ARV) 
regimens for ~8 weeks prior to Scree ning. 
For a list of assess ments at each visit, refer to the Study Proced ures 
Tables in Appe ndix 2: for subj ects in Group 1 can be found in 
Appendix Table 1, for Group 2 in Append ix Table 2 and for Group 3 
in Appe ndix Table 3. Subj ects who achieve SVR 12 will also 
complete the postt reatme nt week 24 visit. 
Screening assess ments will be completed within 28 days of the 
Baseline/Day 1 visit. The screening window can be exte nded up to 
42 days in extenuating circumsta nces, with the a pproval of the 
medical monitor. 
Screening assess ments will include physical examination, medical 
history , height , weight , vital signs , 12-lead electrncardiogra m 
(ECG), adverse events (AEs) relate d to screening proced ures, 
concomi tant medicatio ns, safety laborato 1 y tests (including 
hematology , chemistry, and coag ulation), HCV RNA , serology 
(HIV, HCV, HBV) hemoglobin Ale (HbAlc), assess ment of the 
Page8 02 March 2017 
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 9 02March 2017presence or absence of cirrhosis, screening for hepatocellular 
carcinoma (HCC) for subjects with cirrhosis, serum β -hCG (females 
of child bearing potential only ), HCV genoty ping, IL28B 
genot yping, and serum drug scre en. HIV/HCV co -infected subjects 
will have additional testing for CD4 T -cell count and HIV -1 RNA.
Study  visits will occur at Day  1 and at the end of Weeks 2, 4, 6, and 
8 for subjects in Group 1.
Study  visits will occur at Day  1 and at the end of Weeks 2, 4 , 6, 8, 
and 12 for subjects in Group 2.
Study  visits will occur at Day  1 and at the end of Weeks 2, 4, 6, 8, 
12, 16, 20, and 24 for subjects in Group 3.
On-treatment assessments include adverse events ( AEs), 
concomitant medications, study  medication pill c ount, phy sical 
examination, weight, vital signs, safety laboratory  tests, HCV RNA, 
HBV DNA (for HBcAb+ subjects only ),sparse PK sampling, and 
serum β -hCG (females of child bearing potential only ).HIV/HCV 
co-infected subjects will have additional assessments, including CD4 
T-cell count andHIV-1 RNA assessments.
Single 12- lead ECGs will be collected at Screening, Day 1 (prior to 
study drug administration) ,and at the on-treatment Week 8 
(Group 1), Week 12 (Group 2) and Week 24 (Group 3) visits , or 
Early Termination (ET) visit (if applicable) . At the time of 
collection, ECGs will be reviewed b
yqualified study staff (as 
determined by the investigator) for clinically significant
abnor malities. End of treatment or ET results will be compare d to 
the subject’s Day  1 ECG as part of routine safe
tymonitoring.
All subjects will complete posttreatment visits at Weeks 4 and 12 
after completion of treatment. Subjects who achieve SVR12 will 
also complete the posttreatment Week 24 visit.
Post-treatment assessments include AEs, concomitant medications, 
vital signs, phy sical examination, safety  laboratory  tests, HCV RNA, 
HBV DNA (for HBcAb+ subjects only ),and serum β -hCG (females 
of child bearing potential only ).HIV/HCV co -infected subject s will 
have additional assessments including CD4 T -cell count and HIV -1 
RNA assessments.
HRQoL  survey s (SF -36, CL DQ-HCV, FACIT- F, and WPAI ) will be 
conducted at Day  1, on-treatment Weeks 8 (Group 1), Week 12 
(Group 2), Week 24 (Group 3), or (ET) (if applic able), and 
posttreatment Week 12.
Samples for 
HCV or HIV viral sequencing / phenoty ping will be 
collected at Baseline /Day 1 and every  visit thereafter. 
LDV/SOF 
Protoco l GS-US-337 -4063 
Gilead Sciences , Inc. 
Test Product , Dose, and 
Mode of 
Admini stration: 
Reference Therap y, 
Dose, and Mode of 
Admini stration: 
Criteria for Evaluation: 
Safety: 
Efficacy: 
Phaimacok inetics: 
Statistical Method s: Final 
Amendment 3.0 
LDV/SOF fixed dose combination (FDC) is manufactured as a 
90mg/400mg tablet for oral admini strntio n. Sub' ects will take 
1 tablet dail with or without food. 
None. 
AEs and laborato 1 y tests will be collected throughout the study. 
Efficacy will be evaluated using scheduled assessme nts of HCV 
RNA perfo1med using CO BAS® Amp liPrep® /COBAS® TaqMan® 
HCV Quanti tative Test, v2.0. 
The PK ofLDV and SOF (and metabo lites) may be assessed. 
The prima1 y efficacy endpoint for the study is SVR12 in all enrolled 
and treated subjects. 
In the primaiy efficacy analysis, the point estimate and the 2-si ded 
95% exact confidence interval of SVR 12 rate will be provided for 
each treatment group and overa ll. 
With a sample size of 100 subjects, a 2-sided 95% exact confidence 
interval will extend at the most 20% in length. 
Seco nda1 y efficacy endpoints include SVR4 , SVR24, and the 
propo1iion of subjects with virologic failure. Steady state PK pl asma 
parameters will be listed by subject and sUllllll ai·ized by treatme nt 
group and overall using descriptive statistics for each anal yte 
(SOF [and its metabolites] and LDV, as appropriate). 
This study wi ll be conducted in accorda nce with the gu idelines of Good Clinical Practice (GCP) 
including archiving of essential documents. 
CONFIDENTIAL Page 10 02 March 2017 
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 11 02March 2017GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
° C degrees Celsius
° F degrees Fahrenheit
Ab antibody
ABW Actual body weight
AE(s) adverse event(s)
ALT alanine aminotransferase (also SGPT)
ANC Absolute Neutrophil Count 
aPTT activated partial thromboplastin time
ARV antiretroviral
AST aspartate aminotransferase (also SGOT)
AV atrioventricular
BMD Bone Mineral Density
BMI Body  Mass Index
BW body weight
CD4+ cluster of differentiation 4+
CFR Code of Federal Regulations
CHF congestive heart failure
CI confidence interval
CLCr creatinine clearance rate
CLDQ- HCV Chronic Liver Disease Questionnaire
CM concomitant medication
cm2square centimeter
Cmax the maximum observed serum/plasma/peripheral blood mononuclear (PBMC) 
concentration of drug
CRO contract (or clinical) research organization
CSR Clinical study report
CT Computeri zed T omography
DAA direct -acting antiviral
dL deciliter
DNA deoxyribonucleic acid 
DSPH Gilead Drug Safety and Public Health
ECG electrocardiogram
eCRF electronic case report form
EDC electronic data capture
eg example given
ER Emergency room
ESRD End Stage Renal Disease
ET Early Termination
EU European Union
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 12 02March 2017EudraCT European Union Drug Regulating Authorities Clinical Trials
FACIT -F Fatigue Index
FAS full analysis set
FCF yellow # 6 / sunset yellow FCF aluminum lake
FD&C Federal Food, Drug and Cosmetic
FDA (United States) Food and Drug Administration
FDC Fixed -dose combination
FEV1 forced expiratory volume in 1 second
FSH Follicle stimulating hormone
g grams
GCP Good Clinical Practice
GGT gamma glutamyl transferase
GI giga
GS-7977 formerly PSI-7977
GSI Gilead Sciences, Inc.
GT genotype
h hour
H2 Histamine
Hb Hem oglobin 
HbA 1c Hem oglobin A1c 
HBsAg Hepatitis B surface antigen
HBcAb Hepatitis B core antibody
HBcAb + Hepatitis B core antibody -positive
HBsAb Hepatitis B surface antibody
HBV Hepatitis B virus
HCC Hepatocellular carcinoma
HCV Hepatitis C virus
HDPE High density polyethylene 
HIV Human immunodeficiency virus
HLGT High -Level Group Term
HLT High -Level Term
HMG- CoA 3-hydroxy -3-methyl -glutaryl coenzyme A
HPF high power field
HRQoL Health Related Quality of Life
IB Investigator Brochure
ICF Informed consent form 
ICH International Conference on Harmonization
IEC independent ethics committee
IFN Interferon
IL28B Interleukin -28B gene
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 13 02March 2017IMB Intermenstrual Bleeding
IMP Investigational Medical Product
IND Investigational New Drug (Application)
INR International Normalized Ratio of prothrombin time
IRB institutional review board
IU International Units
IUD intrauterine device
IUS Intrauterine hormone -releasing system
IV Intravenous
IWRS interactive web response system
kg Kilogram
kPa kilopascal
L liter
LAM Lactational amenorrhea method
LDV ledipasvir
LLN lower limit of the normal range
LLOQ Lower limit of quantification
LLT Lower-Level Term
m2 square meter
MCV mean corpuscular volume or mean cell volume
MedDRA Medical Dictionary for Regulatory Activities
mEq milliequivalents
mg milligram
MGB minor groove binder
mL Milliliter
mm3 cubic millimeter
mmHg millimeters mercury
mmol millimole
n number
NS (3/4A/5A/5B) Non-structural Protein
PCR Polymerase Chain Reaction
Peg-IFN pegylated interferon
P-gp P-glycoprotein
PK Pharm acokinetic
PMDA Pharm aceuticals and Medical Devices Agency
PPIs Proton -pump inhibitor
PR P and R w aves (in electrocardiography)
PT preferred term or prothrombin time
Q1 Quartile 1
Q3 Quartile 3
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 14 02March 2017QA Quality assurance
QTc corrected QT
RAV Resistance -associated variants
RBC Red blood cell count
RBV ribavirin
RNA ribonucleic acid
SADR Serious adverse drug reaction
SAE serious adverse event
Scr serum creatinine (mg/dL)
SD Standard deviation
sec seconds
SF-36 36-Item Short Form Health Survey
SGOT Serum glutamic oxaloacetic transaminase
SGPT Serum glutamic -pyruvic transaminase
SNP Single nucleotide polymorphism
SOC System  Organ Class
SOF sofosbuvir, formerly GS -7977
SOP Standard operating procedure
SUSAR Suspected Unexpected Serious Adverse Reaction
SVR Sustained Virologic Response
SVR12 Sustained Virologic Response 12 w eeks after cessation of treatm ent
SVR24 Sustained Virologic Response 24 w eeks after cessation of treatment
SVR4 Sustained Virologic Response 4 w eeks after cessation of treatment
TEN toxic epidermal necrolysis
TND Target not detected
ULN Upper limit of normal
US United States
WBC white blood cell
WPAI Work Productivity and Activity Impairment
β-hCG β-human chorionic gonadotropin
μg microgram
μL microliter
μmol micromole
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 15 02March 20171. INTRODUCTION
Background 1.1.
Hepatitis C virus infection is a global health challenge with the estimated number of persons 
infected ranging from 80 to 150 million worldwide {Gower 2014 , World Health Organization 
(WHO) 201 4}. Hepatitis C virus has significant genetic (RNA sequence) variability  and is 
classified on this bas is into at least 6 genoty pes. There is significant geographical variation in the 
distribution of HCV genoty pes. In North America and Europe, genoty pe1 HCV infection 
predominates. In Asia, genotype 1 and 3 HCV infections are the most prevalent. Genot ype 4, 5,
and 6 are highl y prevalent in northern Africa, southern Africa, and southeast Asia, respectivel y .
The disease burden of HCV infection is due to progression of chronic liver disease, which can 
lead to cirrhosis, liver failure, HCC , and death. Globally , 27% of all subjects with cirrhosis and 
25% of those who develop HCC are attributable to HCV infection {Perz 2006 }. In addition to 
having a higher incidence of HCC , subjects with chronic HCV infection have a higher incidence 
and mortality  of many  types of non -liver cancers including pancreatic , rectal, kidney , 
non-Hodgkin ’slymphoma ,and lung cancers, compared with the general population 
{Allison 2015 }. Curing HCV infection is associated with numerous health benefits including 
more than 70% reduction in the risk of HCC and a 90% reduction in the risk of liver -related 
mortality  and liver transplantation {Morgan 201 3, Poynard 2002 , van der Meer 2012 , 
Veldt 2007 }.
Recently , there has been a transformation in the treatment of HCV infection with the 
development of direct -acting antiviral agents ( DAAs )targeting viral proteins essential to viral 
replication. DAA based treatment regimens are generall y well tolerated and result in high 
sustained virologic response (SVR) at 12 weeks following completion of all treatment (SVR12) 
rates across most patient populations {AbbVie Inc 2016 , Bristol- Myers Squibb 2016 , 
Gilead Sciences Inc 2015a , Gilead Sciences Inc 2015b , Gilead Sciences Inc 2016 , 
Merck &CoInc 2016 }
.SOF based regimens (Sovaldi®and Harvoni®) are the most widely  
prescribed treatments for HCV infection due to the efficacy , tolerability , and simplicity  of the 
dosing regimens. In addition, SOF-based regimens offer the advantages of having relativel y few
drug-drug interactions, strong concordance between clinical trial and “real world” data, and 
absence of a requirement for baseline NS5A polymorphism testing {Arias 2016 , 
Gilead Sciences Inc 2015a , Gilead Sciences Inc 2015b , Ioannou 2016 }.
Despite the progress made in the development of effective treatments for HCV infection, man y
challenges remain. These include the evaluation of DAA based regimens in patient populations 
not evaluated in registration clinical studies, including subjects with advanced hepatic disease, or 
advanced renal di sease and in pediatric populations. In addition, the treatment of populations 
with high HCV prevalence such as the incarcerated, or injection drug users will require the 
development of treatment models tailored to these specific populations. Finally, as th e highest 
prevalence of HCV infection occurs in low and middle income countries, the development of 
treatment algorithms that can be implemented in resource limited settings will be necessary to 
decrease the global prevalence and burden of HCV infection.
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 16 02March 2017Ledipasvir/Sofosbuvir Fixed Dose Combination 1.2.
Ledipasvir is a HCV NS5A inhibitor with potent activity  against genoty pe 1, 4,5,and 6 HCV . 
Sofosbuvir is a nucleotide analog HCV NS5B polymerase inhibitor. LDV/SOF (Harvoni®) is a 
co-formulation of LDV 90 mg a nd SOF 400 mg that is approved in the US, EU ,and other 
regions for the treatment of HCV infection in adults.
1.2.1. General Information
Please refer to the Investigator’s Brochure (IB) for additional information on LDV/SOF , and the 
individual components, includi ng:
In-Vitro Anti -Hepatitis C Virus Activity
Nonclinical Pharmacokinetics and In-Vitro Metabolism
Nonclinical Pharmacology and Toxicology
Clinical Experience
1.2.2. Additional Clinical Information; Study GS -US-334-0154
1.2.2.1. Study  Design
Study  GS-US-334-0154 is a n ongoing Phase 2b, open -label stud y of SOF-based regimens in 
subjects with severe renal impairment. I n Part A, s ubjects with genot ype 1 or 3 HCV infection 
and severe renal impairment were randomized to SOF 200 mg + RBV 200 mg for 24 weeks 
(Cohort 1) or SOF 400mg + RBV 200 mg (Cohort 2) for 24 Weeks . Based on data from 
Cohort 1 and 2, Cohort 3 was opened for enrollment and subjects with genoty pe 1 or 4 HCV 
infection and severe renal impairment were treated with L DV/SOF (90/400 mg) for 12 weeks .
Final data is available for Cohort 1 and Cohort 2 and is presented below . Enrollment in Cohort 3 
is ongoing and preliminary  data is summarized in Section 1.2.2.8 .
1.2.2.2. Disposition (Cohort 1 and 2)
A total of 20 subjects were enrolled and received at least 1 dose of stud y drug; 10 subjects in
Cohort 1 [SOF 200 mg + RBV 200 mg] and 10 subjects in Cohort 2 [SOF 400 mg + RBV 
200mg]. The majority  of subjects (80.0%) completed study treatment (8 subj ects in each 
cohort). Four of the 20 enrolled and treated subjects, prematurel y discontinued study  treatment
(20.0%, 2 subjects in each cohort) . The reasons for premature discontinuation of study  treatment 
were AEs (2 subjects from Cohort 2), n oncompliance with study  drug (1 subject from Cohort 1), 
and withdrawn consent (1 subject in C ohort 1).
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 17 02March 20171.2.2.3. Demographics and Baseline Characteristics (Cohorts 1 and 2)
Demographics and baseline characteristics were similar in both treatment groups. The majorit y 
of subjects were male (70.0%), 45.0% of subjects were black and 35.0% of subjects were white , 
the majority  of subjects were non -Hispanic/Latino (85.0%), and the mean age was 60 years 
(range: 45 −75). The mean (SD) baseline bod y mass index (BM I) for subjects was 
27.3 (3.71) kg/m2and 70.0% of subjects had BMI < 30 kg/m2.
The majority  of subjects had genot ype 1a HCV infection (65.0%, 13 subjects), 20.0% 
(4subjects) had genoty pe 1b, and 15.0% (3 subjects) had genot ype 3a. In Cohort 1, the majority 
of subjects had non -CC (CT or TT) IL28B alleles (80.0%); wh ile 50.0% of subjects in Cohort 2 
had non-CC (CT or TT) IL28B alleles. Overall, the major ity of subjects had HCV RNA 
≥ 6log 10IU/mL (65.0%, 13 subjects), with a mean ( SD) HCV RNA value of 
6.4(0.47) log 10IU/mL . A total of 4 subjects (20.0%, all in Cohort 2) had cirrhosis at screening. 
In Cohort 1 , no subjects reported a known history  of cirrhosis; however, 20.0% (2 subjects) had 
FibroTest scores corresponding to stage of F3 -F4 (severe fibrosis). In Cohort 1, the median 
(range) estimated glomerular filtration rate using the Co ckcroft -Gault equation was 
20.0 (14.4 −35.8) mL/min, and in Cohort 2 it was 25.4 (17.5−39.1) mL/min. The majority  of 
subjects in Cohort 1 (70.0%) were treatment- naive; the 3 subjects who were 
treatment -experienced had failed prior treatment with a DAA + pegy lated interferon (Peg -IFN) + 
RBV regimen (2 subjects) or interferon + RBV (1 subject). The majorit y of subjects in Cohort 2 
(70.0%) were treatment- experienced; the majorit y of these subjects (71.4%, 5 of 7 subjects) had 
failed prior treatment with Peg IFN+RBV.
1.2.2.4. Efficacy  (Cohort 1 and 2)
The SVR12 rates were as follows:
Cohort 1 (SOF 200 mg + RBV 200 mg): 40.0% (95% CI : 12.2% to 73.8%) of subjects
(4of10) achieved SVR12
Cohort 2 (SOF 400 mg + RBV 200 mg): 60.0% (95% CI : 26.2% to 87.8%) of subject s
(6of10) achieved SVR12
In Co hort 1, 6 of 10 subjects (60.0%) did not achieve SVR12: 5 subjects (50.0%) relapsed and 
1subject withdrew consent. I n Cohort 2, 4 subjects (40.0%) did not achieve SVR12; all 
4subjects relapsed. Two of these subjects prematurely  discontinued study  treatme nt on Day  64 
and Day  117, respectively , both due to an AE. No subjects in either cohort had on -treatment 
virologic failure (i .e., breakthrough, rebound, or nonresponse). The concordance observed 
between SVR12 and SVR24 was 100% in both cohorts. HCV RNA lev els (log 10IU/mL) 
declined rapidl y with similar decreases in HCV RNA observed in bot h treatment cohorts. After 
1
week of treatment, the mean (SD) change from baseline in HCV RNA levels was 
−4.41 (0.826) log 10IU/mL in Cohort 1 and –4.68 (0.635) log 10IU/mL in Cohort 2. The decreases 
were maintained from Week 2 through the end of treatment at Week 24.
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 18 02March 2017No nonstructural protein 5B (NS5B) nucleoside inhibitor (NI) resistance -associated variants
(RAVs) were detected in any  of the subjects at baseline. The NS5B N I RAV E237G was 
detected in 3 subjects at the time of relapse (2 with genot ype 1a [1 subject from each cohort] and 
1 with genot ype 1b [Cohort 1]). E237G showed a small reductio n in susceptibility  to SOF 
(1.3-fold change) in a genoty pe 1a replicon assay , which was within assay  variation, and was as 
susceptible as wild -type in the genoty pe 1b replicon assay  (1.0-fold change).
1.2.2.5. Pharmacokinetics/Pharmacod ynamics (Cohort 1 and 2)
SOF AUC tauand C maxwere modestly  higher in subjects receiving the 400- mg dose compared 
with the 200 -mg dose and AUC tauwas generally similar at Week 2 and Week 12 for both doses. 
Compared to historical reference data (SOF US NDA Phase 2/3 HCV- infected subjects without 
renal impairment [creatinine clearance CL cr, ≥ 60 mL /min] adminis tered SOF 400 mg + RBV ± 
Peg
-IFN), dose -adjusted SOF AUC tauand C maxwere ~137% and ~221% hi gher, respectivel y, for 
the 200- mg SOF dose. SOF AUC tauand C maxwere ~36% and ~100% higher than historical 
reference data, respectively , for the SOF 400 -mg dose. C hanges in the PK of GS- 566500 were 
generall y similar to those observed with SOF, consistent with historical data .Higher SOF AUC 
and C max(~503% and ~331%, respectively ) were observed following the SOF 400- mg dose. No 
difference in GS -331007 exposure was o bserved between Week 2 and Week 12, suggesting 
subjects reach edsteady -state by  Week 2. Overall, changes in SOF and GS- 331007 PK were 
consistent with results of Phase 1 Study  P7977 -0915 , which evaluated SOF PK in HCV -negative 
subjects with renal impairment.
Consistent with a long t1/2, RBV exposures in both cohorts were higher at Week 12 compared
with Week 2. The RBV AUC tauand C tauvalues at Week 12 for both cohorts were similar to those
reported for the administration of RBV 1200 mg/day  in subje cts with normal renal function .
1.2.2.6. Safety  (Cohort 1 and 2)
Most subjects (Cohort 1: 60.0%, Cohort 2: 80.0%) received study drug for the protocol -specified 
duration of 24 weeks. In Cohort 1, the proportion of subjects with ≥ 90% adherence to SOF 
(80.0%) was hi gher than to RBV (40.0%). The lower adherence rate to RBV in Cohort 1 was 
primarily  due to intentional RBV dose reductions or interruptions instituted by  site investigators 
for the management of AEs. I n Cohort 2, the proportion of subjects with ≥ 90% adher ence to 
SOF (80.0%) was similar to RBV (70.0%).
Most subjects experienced at least 1 AE (Cohort 1: 100.0%, Cohort 2: 90.0%). In Cohort 1, the 
most commonly  reported AEs (i .e., those occurring in ≥ 2 subjects) were headache (40.0%); 
anemia (30.0%); and hemo lytic anemia, hy poesthesia, insomnia, irritability , muscle spasms, 
pruritic rash, and rash (20.0%, each). In Cohort 2, the most commonly  reported AEs were anemia 
(40.0%) and dizziness (20.0%). Most AEs were of Grade 1 or Grade 2 severity . Grade 3 AEs 
were reported in 2 subjects (20.0%) in Cohort 1 and 3 subjects (30.0%) in Cohort 2. Anemia was 
the only  Grade 3 AE reported in > 1 subject (1 subject in Cohort 1 and 2 subjects in Cohort 2). 
No Grade 4 AEs, deaths, or pregnancies were reported during the study .A total of 4 subjects
(20.0%, 2 subjects in each cohort) had at least 1 treatment
-emergent serious adverse event
(SAE), with no SAEs reported for more than 1 subject. All SAEs were considered by  the 
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 19 02March 2017investigators to be not related to study  drug. A total o f 4 subjects (20.0%, 2 subjects in each
cohort) had AEs leading to premature discontinuation of any  study  drug. The 2 subjects in
Cohort 1 had AEs leading to premature discontinuation of RBV onl y (anemia in 1 subject and
fatigue, irritability , and generali zed rash in 1 subject; all of these AEs were considered to be
related to stud y drug). Of the 2 subjects in Cohort 2 experiencing AEs that led to premature
discontinuation of SOF and RBV, 1 subject had a Grade 2 AE of fatigue that was considered to
be relat ed to study  drug and 1 subject had a Grade 3 AE of renal failure and an SAE of 
pneumonia that were considered to be not related to study  drug.
All subjects had at least 1 laboratory  abnormality  reported. 60.0% of subjects in Cohort 1 and 
70.0% of subjects in Cohort 2 had a Grade 3 or 4 laboratory  abnormality . Across both cohorts, 
the observed Grade 3 or 4 hematology  abnormalities were decreased hemoglobin and 
lymphocy tes. Decreased hemoglobin and decreases in ly mphocy te count are known effects of 
RBV therap y. Across both cohorts, the Grade 3 or 4 chemistry laboratory abnormalities were 
increased creatinine, decreased serum bicarbonate, increased serum glucose, and increased blood 
urea nitrogen. All 5 subjects with Grade 3 or 4 increases in creatinine (2 subj ects in Cohort 1, 
3 subjects in Cohort 2) had Grade 2 or 3 elevations of creatinine at baseline and throughout study  
treatment. The 2 subjects with Grade 3 decreases in serum bicarbonate (1 subject in each cohort) 
had graded decreases in serum bicarbonate at baseline. All 3 subjects with Grade 3 increased 
serum glucose had a medical history  of diabetes. The 1 subject in Cohort 2 who had a Grade 3 
increase in blood urea nitrogen had graded elevations in blood urea nitrogen at baseline and 
throughout stud y treatment.
Overall, there were 3 subjects (15.0%) with an AE under the Renal and Urinary  Disorders
system organ class (SOC): 1 subject in Cohort 1 and 2 subjects in Cohort 2. Of these, 1 subject
(Subject  in Cohort 2 discontinued study  treatment due to a Grade 3 AE of renal
failure and an SAE of pneumonia. The other AEs in the Renal and Urinary  Disorders SOC were
Grade 1 or 2 (chronic kidney  disease and nocturia) that did not lead to modification or
interruption of study  treatment. One subject (S ubject  in Cohort 2 started dial ysis
during the stud y due to worsening of subject’s chronic kidney failure from Stage 4 to Stage 5,
which was considered b y the investigator to be unrelated to stud y treatment.
No subjects had clinically  significa nt ECG abnormalities during treatment with SOF+RBV. No
meaningful change in sy stolic function measured by  ejection fraction was observed in either
treatment cohort. In addition, no subject had a decrease in ejection fraction below 50%. The
median (Q1, Q3) change in ejection fraction from baseline to Week 24 for Cohort 1 was 0.09%
(−0.97, 2.70), and in Cohort 2 was −0.73% (−4.28, 1.08). As compared to baseline
echocardiograms, there were overall no significant changes in fractional shortening, left
ventricul ar end diastolic volume (LVEDV), or left ventricular internal dimension in diastole
(LVIDD) at Week 12 or Week 24.
No notable changes from baseline in vital signs (systolic blood pressure, diastolic blood pressure,
or pulse rate) were observed during the s tudy.
PPD
PPD
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 20 02March 20171.2.2.7. Conclusions (Cohort 1 and 2)
The conclusions for Cohorts 1 and 2 were as follows:
For subjects with severe renal impairment, the overall SVR12 rates following treatment with
SOF (200 mg or 400 mg) in combination with RBV for 24 weeks were as follows:
In Cohort 1 (SOF 200 mg + RBV 200 mg), the SVR12 rate was 40.0%.
In Cohort 2 (SOF 400 mg + RBV 200 mg), the SVR12 rate was 60.0%.
No subjects in either treatment cohort had on-treatment virologic failure (i.e., breakthrough,
rebound, or nonresponse).
Virologic relapse was associated with the emergence of the NS5B NI RAV E237G in 
3
of 9subjects (33.3%).
SOF and GS -331007 exposures in HCV -infected subjects with severe renal impairment in
this study  were higher than exposures observed in the reference US Pha se 2/3 population of
HCV -infected subjects without renal impairment.
SOF AUC tau and C maxwere 36% and 100% higher, respectivel y, for the SOF 400- mg 
dose.
GS-331007 AUC tauand C max were 503% and 331% higher, respectivel y, for the SOF 
400mg dose.
The effect of severe renal impairment on SOF and GS -331007 exposures in HCV
infected subjects administered the SOF 400 mg dose with RBV 200 mg was generall y 
comparable with the results from a dedicated renal impairment study  inHCV -negative 
subjects (Study P7977 -0915).
SOF was safe and well tolerated. The AE and laboratory  safet y profile observed was
consistent with that reported for SOF+RBV in subjects without renal impairment. There were
no new safety signals or toxicities observed in this study  of subjects with se vere renal
impairment.
1.2.2.8. Preliminary  Data from Cohort 3
As of August 2016, 10 subjects have been enrolled and treated in Cohort 3. Preliminary  data 
suggest LDV/SOF has been well tolerated. No subjects have discontinued treatment. There have 
been 4 SAEs repor ted; hy pogly cemia and s yncope in one subject (Subject  and 
acute renal failure (Subject  in one subject, and acute kidney  injury  in one subject 
(Subject  The sy ncope experienced by  Subject  was assessed as 
secon dary to hy poglycemia. No SAE was assessed as related to study  drugs. An anal ysis of 
echocardiogram data for 8 subjects demonstrates stable parameters from screening through the 
PPD
PPD
PPD
PPD
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 21 02March 2017end of treatment, and does not suggest an impact of LDV/SOF treatment on cardia c function. 
Eight subjects who have reached posttreatment Week 12 to date have achieved SVR12 (100%, 
8/8).
1.2.3. Additional Non -Clinical Toxicology Information
In dogs, repeated administration of GS -9851 (the diastereomeric mixture of SOF and 
GS-491241) or SOF at exposures similar to those expected in ESRD patients may  decrease 
erythropoiesis and lower the numbers of circulating red cells (reflected by  the decrease in red 
blood cells, hemoglobin concentration, and/or hematocrit). In the 4 -and 13 -week studies in dogs, 
there were slightly  lower average circulating red cell indices, and minimally  decreased 
erythropoiesis (observed by  bone marrow cy tology ) at 500 and ≥ 100 mg/kg/day , respectively . 
However, in the 39 -week dog study , while minimally  decreased ery throp oiesis was observed in a 
few dogs, there were no SOF -related effects on circulating red cell indices at 500 mg/kg/day . In 
mice and rats, SOF did not affect hematology  parameters at an y dose level; specificall y, there 
were no effects in mice dosed up to 100 0 mg/kg/day  for up to 13 weeks or in rats dosed up to 
500 mg/kg/day  for up to 26 weeks. There were also no bone marrow cy tology  findings in rats 
dosed up to 26 weeks. In vitro, the diastereomic mixture GS -9851 also showed low cytotoxicity  
to ery throid cell lines.
Rationale for This Study 1.3.
The GS -US-337-4063 study  is a Phase 2, open -label ,multicenter study  evaluating the efficacy  
and safet y of treatment of LDV/SOF for 8, 12, or 24 weeks in subjects on dialy sisfor ESRD . 
Approximately  100 subjects will be enr olled .
LDV/SOF (Harvoni®) is approved in the US, EU ,and other regions for the treatment of genot ype 
1,3 (EU only), 4, 5, and 6 HCV infection . However, subjects with severe renal impairment were 
not eligible for the registration LDV/SOF clinical studies. There is therefore no dosing 
recommendation provided for HCV -infected subjects with severe renal impairment or those on 
dialy sisin the prescribing information in the US, EU ,and other regions.
There remains a medical need for highl y effective treatment fo r HCV -infected subjects with 
ESRD on dialy sis. Chronic HCV infection has a significant negative impact on morbidity  and 
mortality  in subjects on dialy sis {Fabrizi 2007 }. The Kidney  Disease International Working 
Group (KDIGO) recommend that HCV infection be treated prior to kidney  transplant as there is 
evidence that this leads to improved graft and patient outco mes {Kidney  Disease: Improving 
Global Ou tcomes 2008 }.
Although, some regions do have approved HCV treatment options for HCV -infected subjects
with severe renal impairment including Viekira Pak®and Zepatier ™ {AbbVie Inc 2016 ,
Merck & Co Inc 2016 }, both regimens have limitations. The use of Viekira Pak®is limited since
many  populations require the addition of ribavirin for optimal efficacy  and RBV -induced 
toxicit ies are exacerbated in subjects with renal impairment. In addition, the components of 
Viekira Pak®(ombitasvir, paritaprevir, ritonavir ,and dasabuvir) have drug -drug interaction 
potential which adds increasing complexity to the management of subjects with severe renal 
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 22 02March 2017impairment who frequently  have multiple comorbid conditions and concomitant medications. 
The use of Zepatier is limited by  the requirement for baseline resistance testing for subjects with 
genot ype 1a infection and addition of RBV is required for some populations. Furthermore, both 
regimens carry  the risk of alanine aminotransferase (ALT) elevations and/or hepatotoxicity and 
neither regimen is pangenoty pic.
SOF-based regimens are currentl y the most wide lyprescribed treatments for HCV infection. 
Despite the lack of dosing recommendations for subjects with severe renal impairment in the 
prescribing information for SOF -based regimens, it is apparent from the number of publications 
of small cohort studies describing treatm ent of subjects with severe renal impair ment with 
SOF-based regimens that such treatment is not uncommon {Bhamidimarri 2015 , Desno yer 2016 , 
Hundemer 2015 , Navarro -Millan 2013 , Nazario 2016 }. The simplicity of SOF -based dosing 
regimens, relative lack of dru g-drug interactions, and absence of a requirement for baseline 
NS5A po lymorphism testing or RBV use makes SOF-based regimens a viable option for 
physicians, even when considering the l ack of dosing recommendations in this population. 
The unmet medical need of the population and the ongoing of f
-label use of S OF-based regimens 
provide a strong rationale for the conduct of this study as the data obtained will address the gaps 
in knowledge regarding the use of SO F-based regimens in subjects with HCV infection who are 
on dialy sis for ESRD .
Rationale for Dose Selec tion of LDV/SOF 1.4.
Subjects in this study  will be administered LDV/SOF, a co-formulation of LDV 90 mg and SOF 
400 mg that is approved in the US , EU,and other regions as Harvoni®for the treatment of HCV 
infection in adults. The treatment durations evaluated are aligned with those outlined for 
RBV -free treatment in the EU prescribing information for subjects without cirrhosis or with 
compensated cirrhosis; specificall y
Subjects who are treatment naïve and without cirrhosis; L DV/SOF for 8 weeks
Subjects who are treatment experienced and without cirrhosis: L DV/SOF for 12 Weeks
Subjects who have compensated cirrhosis: L DV/SOF for 24 weeks
The results of a Phase 1 single dose stud y of LDV in subjects with severe renal impairment 
indicates that no relevant differenc es in LDV exposure were observed between subjects with 
normal renal function and subjects with severe renal impairment. In a Phase 1 study  of the PK of 
SOF in subjects with renal impairment , the SOF and GS -331007 AUC were 171% and 451% 
higher , respectivel y,in subjects with severe renal impairment compared to subjects with normal 
renal function . In subjects with ESRD, SOF and GS -331007 AUC was 28 -60% and 1280 -2070 % 
higher , respectivel y,compared to subjects with normal renal function.
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 23 02March 2017Available data from th e Study GS-US-334-0154 indicates that administration of SOF 400 mg 
with RBV 200 mg for 24 weeks in subjects with severe renal impairment was well tolerated with 
no specific safet y signal associated with the elevated exposures of SOF or the predominant 
meta bolite GS -331007. The exposure sof SOF and GS -33100 7 in the GS -US-334-0154 study  are
consistent with the results of the Phase 1 study of SOF in subjects with severe renal impairment 
or ESRD . Preliminary  data from the GS -US-334-0154 study  suggests that the administration of 
LDV/SOF (90/400 mg) for 12 weeks is well tolerated and is more efficacious that administration 
of SOF 200 mg o r 400 mg with RBV 200 mg for 24 weeks. 
Based on thes e data , theapproved dose of LDV/SOF will be evaluated in this study . Refer to the 
LDV/SOF IBfor additional information .
Risk/Benefit Assessment for the Study 1.5.
This study  will provide data of the safet y and efficacy of LDV/ SOF in subjects with ESRD on 
dialy sis. It is anticipated that these data will support dosing recommendat ions for LDV/SOF in 
subjects with severe renal impairment and subjects with ESRD on dialy sis.
The potential benefits of LDV/SOF over the currently  available treatment options are:
LDV /SOF has broad antiviral activity  against a range of HCV genotype s; it is currently 
approved in the US and EU for the treatment of genot ypes1,3(EU only), 4, 5,and 6 HCV 
infection . LDV /SOF may therefore provide a treatment option for a broader range of HCV 
infected subjects with severe renal impairment and E SRD on dialysis thanthecurrently  
available treatment options which are restricted to the treatment of genotype 1 and 4 HCV 
infections .
LDV/ SOF will provide a highl y effective and well -tolerated RBV -free treatment option for 
subjects on dialy sis. As RBV -associated toxicities can be exacerbated in subjects with severe 
renal impairment, the availability  of a RBV -free treatment option will enable a greater 
proportion of subjects with ESRD to be treated. 
The components of LDV/ SOF have limited drug -drug interaction potential with medications 
commonly  prescribed to subjects with sever erenal impairment or ESRDon dialy sis. This 
should reduce the complexity  of patient management compared with the use of other antiviral 
treatments.
The risks associated with the evaluations of LDV/SOF in subjects with E SRDon dialy sis are 
associated with concerns about the high exposure of the predominant SOF metabolite, 
GS-331007, in subjects with renal impairment and the limited data on the safet y and efficacy  of 
LDV/SOF in subjects with renal impairment .In non -clinical studies, GS -331007 exposure 
similar to that projected for patients with ESRD administered L DV/SOF resulted in decreased 
red cells counts (See Section 1.2.3 ).
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 24 02March 2017These risks are mitigated by the following :
Approximately  5000 subjects have been administered LDV/SOF with or withou tRBV to 
date.
During the conduct of the study , hematologic assessments will be performed routinely  and 
results will be reviewed by  the investigator and sponsor. 
During the conduct of the study , a Data Monitoring Committee (DMC) will evaluate safety  
data in the study  after the first n= 12subjects have completed 8 weeks of treatment , or early  
termination (ET) ,and then every  3 months until the last subject enrolled co mpletes treatment 
with study  drugs . Furthermore, the Sponsor and the Investigators will perform ongoing safet y 
reviews throughout the study .
Given the medical need for a well -tolerated, highly  effective, RBV -free treatment options for 
HCV infected subjects with ESRD on dialy sis;the benefit/risk assessment of this study  favors 
the conduct of the stud y.
Compliance 1.6.
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 25 02March 20172. OBJECTIVES
The primary objective sof this study are as follows :
To evaluate the antiviral efficacy  of treatment with LDV/SOF for 8,12 ,or 24 weeks in 
subjects with chronic hepatitis C virus (HCV) infection who are on dial ysis for ESRD , as 
measured b y the p roportion of subjects with sustained viral response 12 weeks after cessation 
of treatment (SVR12)
To evaluate the safet y and tolerability  of each treatment regimen
The secondary objectives of this study are as follows: 
To determine the proportion of subje cts who attain SVR at 4 and 24 weeks after cessation of 
each stud y treatment regimen (SVR4 and SVR24)
To evaluate the proportion of subjects with virologic failure
To evaluate the kinetics of circulating HCV RNA during treatment and after cessation of 
treatment 
To evaluate the emergence of viral resistance to LDV and SOF during treatment and after 
cessation of treatment
To evaluate the stead y-state pharmacokinetics of LDV and SOF ,and its metabolites in 
subjects who are on dialysis for ESRD
The exploratory objective sof this study are:
CCI
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 26 02March 20173. STUDY  DESIGN
Study Design 3.1.
This is a multicenter, open -label Phase 2study  that will evaluate the safety , tolerability ,and 
antiviral efficacy  of LDV/SOF in subjects ondialysis for ESRD with genotype 1, 4, 5, or 6HCV 
infection .
Visit Schedule 3.2.
Screening assessments will be completed within 28 days of the Day 1 visit. The screening 
window can be extended to 42 day s for extenuating circumstances with Sponsor approval.
All subjects will complete the following stud y visits: Screening, Day  1, on -treatment visits at the 
end of W eeks 2, 4, 6, and 8. Subjects in group 2 and 3 will also complete a Week 12visit, and 
subjects in group 3 onl y, will also complete visit at Weeks 16, 20, and 24. All subjects will 
complete posttreatment visits at Weeks 4 and 12, after completion of treatment. Subjects who 
achieve SVR12 will also complete the posttreatment Week 24 visit.
Duration of Treatment 3.3.
Approximately  100 subjects will be enrolled to one of 3 groups and will receive treatment with 
LDV/SOF for 8, 12, or 24 weeks. The treatment group to which subjects are assigned will be 
determined b y genotype, the absence or presence of cirrhosis and whether the subject is 
treatment naïve or treatment experienced. 
Group 1: Treatment naïve g enotype 1 subjects without cirrhosis will be treated with LDV/SOF 
for 8 weeks
Group 2: Treatment experienced g enotype 1 subjects and treatment naïve or treatment 
experienced genot ype 4, 5, and 6 subjects without cirrhosis will be treated with 
LDV/SOF for 12 weeks
Group 3: Subjects with compensated cirrhosis will be treated with L DV/SOF for 24 weeks
The total time to complete all study  visits is up to a maximum of 52 weeks depending on the 
treatment duration (54weeks for those requiring an extension of the screening period):
28 day s (4 weeks) screening period (or 42 days for extenuating circumstances )
8, 12 , or 24 week stud y treatment period
24 week posttreatment period
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 27 02March 2017Stopping Rules and Discontinuation Criteria 3.4.
If a subject discontinues study  dosing (for example, as a result of an adverse event [AE]), every
attempt should be made to keep the subject in the study ,and continue to perform the required
study -related follow -up procedures ( Section 6.4). If this is not possible or acceptable to the
subject or Investigator, the subject may  be withdrawn from the study .
There is no option for LDV/SOF dose reduction due to toxicity . If LDV/SOF is withheld due to 
toxicity , the subject must discontinue treatment and complete an ET visit.
For subjects who have completed an ET visit, the posttreatment Week 4 and 12 visits will be
scheduled after last dose of an yof the stud y drug. Subjects who achieve SVR12 (HCV RNA 
<LLOQ at posttreatment Week 12) will complete the posttreatment Week 24 visit.
When medically  feasible, the medical monitor must be consulted prior to subject discontinuation.
Study  drug(s) must be d iscontinued in the following instances:
Unacceptable toxicity  (as defined in Section 3.4.1 )or toxicity  that, in the judgment of the 
investigator, compromises the ability  to continue study -specific procedures or is considered 
to not be in the subject’s bes t interest
Virologic failure (as defined in Section 3.4.2 )
Pregnancy  of female subject (refer to Appendix 4)
Significant protocol violation that impacts subject safet y
Subject request to discontinue for an y reason; it is important to determine whether the
withdrawal of consent is primarily due to an AE, lack of efficacy, or other reason
Subject noncompliance
Discontinuation of the study  at the request of Gilead, regulatory  agency  or an Institutional
Review Board (I RB)/Independent Ethics Committee (IEC)
3.4.1. Toxicity -Based Stopping Criteria
Subjects who meet an y of the following laboratory or adverse event criteria must stop treatment 
with LDV/SOF :
Elevation of ALT and/or AST above the upper limit of normal and > 5x Day 1 or nadir, 
confirmed b y immediate repea t testing
Elevation of ALT > 3 x Day  1 andtotal bilirubin > 2 x UL N, confirmed b y immediate repeat 
testing
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 28 02March 2017Elevation of ALT > 15 x ULN, confirmed b y immediate repeat testing
Any Grade 3 or greater rash associated with constitutional sy mptoms
Any Grade 4 a dverse event assessed as related to LDV/SOF
3.4.2. Virologic Response Base Stopping Criteria
The following on- treatment virologic response -based treatment stopping criteria will be utilized:
Confirmed HCV RNA ≥ LLOQ after 2 consecutive HCV RNA < LLOQ
Confirmed > 1 log 10 increase from on -treatment nadir
HCV RNA ≥LLOQ at Week 8
Confirmation should be performed as soon as possible and must occur no later than 2 weeks after
an initial observation indicating virologic failure during the on -treatment phase. All subjects who 
terminate treatment earl y will complete the ET visit and posttreatment Week 4 and 12 visits.
HIV Virologic Rebound Criteria 3.5.
Subjects who have at least two consecutive post -baseline visit plasma HIV -1 RNA levels 
≥400copies/mL  (at least two weeks apart) will be considered to have HIV virologic rebound. 
Following an initial HIV -1 RNA result of ≥ 400 copies/mL , subjects will continue to take their 
current ARV regimen and be asked to return to the clinic after 2 weeks for a scheduled or 
unschedul ed blood draw for confirmation of HIV virologic rebound. If HIV virologic rebound is 
confirmed at the scheduled or unscheduled visit, the blood samples from this visit will be used 
for HIV -1 genot ype/phenotype testing. If no resistance to the subject’s cur rent ARV regimen is 
detected, the subject may continue on the current ARV regimen.  
HCV study  drug should be continued unless safety  events warrant the discontinuation of the 
study  drug, as outlined is Section 3.4of the protocol.
Please refer to Figure 3-1for the management of subjects who meet the criteria for HIV virologic 
rebound .
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 29 02March 2017Figure 3-1. HIV Virologic Rebound Schema
a HCV study drug should be continued unless safety events warrant the discontinuation of these study drugs, as outlined in
Section 3.4of the protocol
b If virologic rebound is not confirmed, the subject should remain on their current ARV regimen.
c If virologic rebound is confirmed, the HIV-1 genotype and phe notype (reverse transcriptase and protease) should be 
analyzed. Based on the results of the genotype and phenotype assays, the subject may remain on their ARV regimen or a 
new ARV regimen may be configured at the discretion of the Investigator . If the genotype and/or phenotype assay fails to 
provide results, a new ARV regimen may be configured at the discretion of the Investigator in consultation with the Medical
Monitor.HIV-1 RNA ≥ 400 copies/mL
Continue current ARV regimen and return for 
scheduled/unscheduled (at least 2 weeks apart) HIV-1 
RNA and potential genoty pe/phenoty pe samplinga
HIV-1 genot ype/phenot ypeUnconfirmed 
virologic re bound: 
remain on current 
regimenbConfirmed virologic reboundc
If no resistance to the subject’s current 
ARV regimen is detected, may  
continue on current ARV regimenStudy  Period
(On-Treatment)
If resistance to the subject’s current 
ARV regimen is detected, 
discontinue and construct a new 
ARV regimen  
  
LDV/ SOF 
Protocol GS-US-337-4063 
Gilead Sciences, Inc. 
3.6. 
3.6.1. 
I 
3.6.2. 
Biomarker Testing 3.7. 
3.7.1. Sample s for Optional Future Research 
CONF IDENTIAL Page 30 Final 
Amendment 3.0 
02 March 2017 
LDV/SOF 
Protocol GS-US-337 -4063 
Gilead Sciences , Inc. 
3.7.2. 
CONFIDENTIAL Page 31 Final 
Amendment 3.0 
02 March 2017 
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 32 02March 20174. SUBJECT POPULA TION
Approximately  100 subjects will be enrolled in this study . In order to manage the total study  
enrollment, Gilead Sciences, Inc., at its discretion, may suspend screening and/or enrollment at 
any site or study -wide at any  time.
Inclusion Criteria 4.1.
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study .
1)Willing and able to provide written informed consent
2)Male or female age ≥ 18 y ears
3)Chronic HCV infection ( ≥ 6 months) as documented by prior medical history or liver biops y
4)HCV RNA ≥ LLOQ at screening
5)Genoty pe 1,4,5,and 6 HCV as determined at Screening
6)End stage renal disease (ESRD) requiring peritoneal dial ysis (PD) or hemodialy sis (HD)
7)The most recent HCV treatment must have been completed at least 8 weeks prior to screening
8)Subjects must have a determination of treatment experience (treatment naïve v s. treatment 
experienced). Treatment naïve is defined as having never been exposed to an approved or 
experimental HCV -specific direct acting antiviral agents or prior treatment of HC V with 
interferon or ribavirin. Al l other subjects will be considered treatment experienced .
9)Subjects must have appropriate testing for determination of cirrhosis status.
a)Presence of cirrhosis is defined as an y one of the following:
i)Fibroscan with a result of > 12.5 kPa 
ii)Liver biopsy  showing cirrhosis (e.g., Metavir score = 4 or Ishak score ≥ 5)
iii)In the absence of liver biopsy  or availability  of Fibroscan, FibroTest® score ≥ 0.75 
at screening
b)Absence of cirrhosis is defined as an y one of the following:
i)Fibroscan with a result of ≤ 12.5 kPa within ≤ 6 months of Baseline/Day  1
ii)Liver biopsy  performed within 2 y ears of Screening showing absence of cirrhosis
iii)In the absence of liver biopsy  or availability  of Fibroscan, FibroTest® score < 0.75 at 
screening
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 33 02March 201710)Liver imaging within 6 months of Basel ine/Day  1 is required in cirrhotic subjects only ,to 
exclude HCC
11)Subjects with HI V-1 coinfection may  be eligible, provided they  satisfy these additional 
inclusion criteria:
i)Completed at least 3 months of any prior HIV ARV therap y and maintained HIV 
RNA<50 copies/mL (or <LLOQ if the local laboratory  assay ’s LLOQ is 50≥ copies/ mL) 
and CD4 T-cell count > 100 cells/mm3prior to Screening. Subjects with an isolated or 
unconfirmed HIV RNA >50 copies/mL (or >LLOQ if the local laboratory  assay ’s LLOQ 
is 50 ≥ copies /mL) are not excluded
ii)On a stable ARV regimen for ≥ 8 weeks prior to Screening and is expected to continue 
the current ARV regimen through the end of stud y (See exclusion criteria 16). 
12)A negative serum pregnancy test is required for female subjects (unles s permanently  sterile 
or greater than two years post -menopausal).
13)Male subjects and female subjects of childbearing potential who engage in heterosexual 
intercourse must agree to use protocol specified method(s) of contraception as described in
Appendix 4.
14)Lactating females must agree to discontinue nursing before the study drug is administered.
15)Subject must be able to comply  with the dosing instructions for study  drug administration 
and able to complete the study  schedule of assessments
Exclusion Criteria 4.2.
Subjects who meet anyof the following exclusion criteria are not to be enrolled in this study .
1) Curr ent or prior history  of any  of the following:
a)Clinically -significant illness (other than HCV , HIV and kidney  disease or co -morbidities 
associated with ESRD except as noted below )any other major medical disorder that may  
interfere with subject treatment, assessment or compliance with the protocol ; subjects 
currentl y under evaluation for a potentially clinically significant illness (other than HCV
or ESRD ) are also excluded .
b)Current or prior history  of significant cardiac disease including or resulting in: 
Hospital admission for significant cardiovascular disease (m yocardial infarction, 
unstable angina, heart failure, hypertensive emergency) or has had a cardiovascular 
procedure ( e.g.CABG or PTCA), within 6 months of Screening
Cardiomy opath ywith ejection fraction <50%
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 34 02March 2017c)Gastrointestinal disorder or postoperative condition that could interfere with the 
absorption of the study  drug.
d)Difficulty with blood col lection and/or poor venous access for the purposes of 
phlebotomy .
e)Clinical hepatic decompensation (i.e., ascites, encephalopathy  or variceal hemorrhage).
f)Solid organ transplantation other than failed kidney  transplants ( current use of ≤5 mg/day  
of prednisone, or equivalent dose of corticosteroid, allowed ).
g)Significant pulmonary  disease
h)Psychiatric hospitalization, suicide attempt, and/or a period of disability  as a result of 
their psy chiatric illness within the last 2 y ears.
i)Malignancy within the 5 years prior to screening, with the exception of specific cancers 
that have been cured b y surgical resection (basal cell skin cancer, etc). Subjects under 
evaluation for possible malignancy  are not eligible
2)Screening ECG with clinically  signif icant abnormalities
3) Chronic liver disease of a non- HCV etiology  (e.g., hemochro matosis, Wilson’s disease, 
alfa-1 antitry psin deficiency , cholangitis).
4)Opportunistic infection (Appendix 5)within 6 months prior to Screening
5)Infection (other than HIV or HCV) requiring pa
renteral therap y within 30 days prior to 
baseline.
6) Life threatening SAE during the screening period
7)Subjects ha vethe following laboratory  parameters at screening:
a)ALT > 10 X the upper limit of normal (ULN)
b)AST > 10 X ULN
c)Direct bilirubin > 1.5 X ULN. For subjects receiving ritonavir boosted atazanavir 
regimen, a direct bilirubin > 1.5 xULNwill be allowed if < 25% of the total bilirubin
d)Platelets < 25,000/ μL
e)HbA1c > 9%
f)Hemoglobin < 9 g/dL
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 35 02March 2017g)Albumin < 2.8 g/dL
h)INR > 1.5 x UL N unless subject has known hemophi lia or is stable on an anticoagulant 
regimen affecting INR
i)Hepatitis B surface antigen positive
8)Prior exposure to any  HCV NS5A inhibitor.
9)Male with pregnant female partner.
10)Females who may  wish to become pregnant and/or plan to undergo egg harvesting during the 
course of the stud y and up to 30 day s of the last dose of study  drug
11)Males who may  wish to donate sperm during the course of the study  until at least 30 day s 
after the last dose of study  drug.
12)Clinically -relevant alcohol or drug abuse within 12 months of screening. A positive drug 
screen will exclude subjects unless it can be explained by  a prescribed medication; the 
diagnosis and prescription must be approved b y the investigator.
13)Use of an y prohibited concomitant medications as described in Sec tion5.4.
14)Chronic use of s ystemically  administered immunosuppressive
agents (e.g., prednisone 
equivalent > 10 mg/day ).
15)Known hy persensitivity  to L DV, SOF, the metabolites, or formulation excipient.
16)For subjects with HIV -1 coinfection onl y:
HIV-1 RNA >50 co pies/mL
CD4 T -cell count <100 cells/mm3
HIV-2 positive test
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 36 02March 20175. INVESTIGA TIONAL  MEDI CINAL  PRODUCTS
Randomization, Blinding and Treatment Codes 5.1.
This is an open -label study. An Interactive Web Response S ystem (IWRS) will be emplo yedto
manage subject enrolment and the study drug dispensing as well as r e-suppl y ofstudydrug.
Description and Handling of LDV/SOF FDC 5.2.
5.2.1. Formulation
LDV/SOF FDC tablets are orange, diamond -shaped, film -coated tablets containing 90 mg of 
LDV and 400 mg of SOF . The tablets are debossed wi th “GSI” on one side and “7985” on the 
other side. In addition to the active ingredients, the LDV/SOF FDC tablets contain the following 
inactive ingredients: lactose monohy drate, copovidone, microcry stalline cellulose, 
croscarmellose sodium, colloidal sili con dioxide, magnesium stearate, pol yviny l alcohol, 
titanium dioxide, talc, poly ethyleneglycol and FD&C y ellow # 6 /sunset y ellow FCF aluminum 
lake.
5.2.2. Packaging and Labeling
LDV/SOF FDC tablets are packaged in white, high density  polyethylene (HDPE) bottles . Each
bottle contains either 28 or 30 tablets ,a silica gel desiccant canister and poly ester packing 
material. Each bottle is enclosed with a white, continuous thread, child -resistant screw cap with 
an induction -sealed, aluminum -faced liner.
All L DV/SOF FDC bottles to be distributed to centers in the EU, North America and 
Asia Pacific shall be label led to meet all applicable requirements of the US Food and Drug 
Administration (FDA), Annex 13 of Good Manufacturing Practices: Manufacture of 
investigational medicinal products and local regulations as applicable.
5.2.3. Storage and Handling
LDV/SOF FDC bottles should be stored at controlled room temperature until required for 
administration. Controlled room temperature is defined as 25 C (77 F); excu rsion s are permitted 
between 15 C and 30 C (59 F to 86 F).
All drug products should be stored in a secure ly locked area, accessible only to authorized site 
personnel. To ensure the stabilit yofthestudy drug and to ensure proper product identification, 
the drug product should not be stored in a container other than the container in which they are 
supplied. Consideration should be given to handling, preparation, and disposal through measures 
that minimize drug contact with the bod y. Appropriate precautions sh ould be followed to avoid 
direct e ye contact or exposure through inhal ation w hen handling LDV/SOF FDC .
Sufficient quantities of LDV/SOF FDC tablets to complete the entire stud y will be shipped to the 
investigator or qualified designee from Gilead Clinical Supply  Management Team (or its 
designee).
LDV/ SOF 
Protocol GS-US-337-4063 
Gilead Sciences , Inc. 
5.3. Dosage and Administration of LDV /SOF FDC 
LDV /SOF FDC ta blet is to be administe red on ce dail with or w ithout food. Final 
Amendment 3.0 
For a missed dose ofLD V/SOF FDC tablet, subj ects should be instructed to take the missed dose 
of study drng as soon as possible durin g the same d ay. Subjects sho uld be cautioned never to 
double the next dose with a missed dose of study drng under any c ircumstances. 
Study chugs should not be cut or split. LDV/SOF tablets will be provide d by Gilead Sciences for 
all subjects. 
5.4. Prior and Concomitant Medications 
Concomitant medicatio ns taken within 30 days prior to scree ning, up to and inclu ding 30 days 
after the last dose of study drng, need to be recorded in the source documents and elech'o nic case 
repo1 i fonn(s) (eCRFs). 
The following medicatio ns are prohibited during the screening period and for a minimum of 
28 days prior to the Day 1 visit through the end of ti·eatinent: 
• Gr anulocyte colony stimulating facto rs (GCSF) and th rombopoietin (TPO) mim etics 
• Investigatio nal agents or devices for any indica tion 
• Ch ronic use of syste mic immun osuppressants including, but not limited to, co1iicos teroids 
(prednisone equivalent of> 10 mg/day for > 2 weeks) , azathiop1ine, or mon oclonal 
antibod ies (e.g., infliximab. 
Concomitant use of ce1ia in medica tions or h erbaVnat ural supplements (inhibitors or inducers of 
dmg ti·anspo1 iers, i.e., BCRP and P-gp) with study ch11 g may result in PK interactio ns resultin g 
in increases or decreases in exposure of study chug. 
The use of amio darone is prohibited from 60 days prior to Day 1 through the end of ti·eatinent; 
other examples of representative medicatio ns w hich are prohibited or are to be used with caution 
from 21 days prior to Day 1 through the end of ti·eatinent are listed below in Table 5-1. 
CONF IDENTIAL Page 37 02 March 2017 
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 38 02March 2017Table 5-1. Disallowed and Concomitant Medications to be Used with Caution
Drug Class Agents Disallowed Use with Caution
Acid Reducing Agentsa Proton -Pump Inhibitors, 
H2-Receptor Antagonists, Antacids
Anticonvulsantsb Phenobarbital, Phenytoin, Carbamazepine, 
Oxcarbazepine
AntimycobacterialsbRifabutin, Rifapentine, Rifampin
Cardiac Medications AmiodaronecDigoxind
Herbal/Natural SupplementsbSt. John’s Wort, Echinacea, Milk thistle 
(i.e., silymarin), Chinese herb sho -saiko -to 
(or Xiao -Shai-Hu-Tang)
HMG -CoA Reductase 
Inhibitorse Rosuvastatin
a It is recommended to separate antacid and LDV/SOF administration b y 4 hours. H2-receptor antagonists may be 
administered simultaneously with or staggered from LDV/SOF at a dose that does not exceed doses comparable to
famotidine 40 mg twice daily. Proton-pump inhibitor doses comparable to omeprazole 20 mg can be administered 
simultaneously with LDV/SOF. Proton -pump inhibitors should not be taken before LDV/SOF. 
b May result in a decrease in the concentrations of study drug.
c May result in symptomatic bradycardia. Mec hanism is not currently known. The use of amiodarone is prohibited from 
60days prior to Baseline/Day 1 through the end of treatment. 
d May result in an increase in the concentration of study drug and/or concomitant medications. Co-administration of 
LDV/SOF with digoxin may increase the concentration of digoxin. Caution is warranted and therapeutic concentration 
monitoring of digoxin is recommended when co -administered wi th LDV/SOF. 
e Use with study drug may result in an increase in the concentration of rosuvastatin. Monitor for signs and symptoms of 
muscle weakness or myopathy, including rhabdomyolysis.
Medications for disease conditions excluded from the protocol (e.g., active cancer) are not listed 
under this Concomitant Medication section and are disallowed in the study.
Should subjects have a need to initiate treatment with any excluded concomitant medication, the
Medical Monitor must be consulted prior to initiation of the new medication. In insta nces where 
an excluded medication is initiated prior to discussion with the Sponsor, the Investigator must
notif yGilead as soon as he/she is aware of the use of the excluded medication.
Accountability forLDV/SOF FDC 5.5.
The investigator or designee (i.e., pharmacist) is responsible for ensuring adequate accountability 
of all used and unused study  drug .This includes acknowledgement of receipt of each shipment 
of study  drug (quantity  and condition). All used and unused study drug dispensed to subjects 
must be returned to the site.
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 39 02March 2017LDV/SOF FDC accountability  records will be provided to each study  site to:
Record the date received and quantity  of study  drug kits
Record the date, subject number, subject initials, the study  drug kit number dispensed
Record the date, quantity of used and unused study  drug returned, along with the initials of 
the person recording the information.
5.5.1.
Investigational M edicinal Product Return or Disposal
Please refer to Section 9.1.7 for information pertaining to stud y drug return and disposal.
LDV/ SOF 
Protocol GS-US-337-4063 
Gilead Sciences , Inc. 
6_ STUDY PROCEDURES Final 
Amendment 3.0 
The study proced ures to be conducted for each subj ect enrolled in the s tudy are pr esented in 
tabular f01m in Appendix 2 and descr ibed in the text that follows. Additional info1mation is 
prov ided in the study proced ures manual. 
The investigator must document any d eviatio n from p rotocol proced ures and notify the sponsor 
or contract researc h organizatio n (CRO) . 
6.1. 
6.1.1. 
6.1.1.1. Subject Enrollment and Treatment Assignment 
Pretreatment Assessment s 
Scree ning Visit 
Subjects will be screened wit hin 28 days of the Day 1 visit before enrollment to detennin e 
eligibility for paiiicipatio n in the study. The scree ning window can be extended up to 42 days for 
subjects requirin g additional H CV genotyp ing (if initial testing is inconclusive) or for 
extenuating circumstances with Sponsor approva l. 
The following will be perfo1 med and documented at screening: 
• O btain written info1med consent 
• D etennin e inclusion and exclusion e ligibility 
• Ob tain medical histo1y, including: 
- D etennin ation of treat ment experience (treatment nai've vs. treatment experienced). 
Trea tment nai've is defined as having never been exposed to an approved or 
expe rimental HCV-specific direct acting antiviral agents or prior treatment ofHCV 
with interferon or ribavirin. All other su bjects will be considered tr eatment 
experienced. 
- H epati tis C histo1 y 
Regi men( s) 
Dates of previous treatment(s) 
CONF IDENTIAL Page 40 02 March 2017 
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 41 02March 2017Response to previous treatment (e .g., non- responder, relapse, discontinuation including 
reason)
Renal 
dialysis history
■Type: hemodialy sis or peritoneal dialy sis
■Date of initiation
■Stop date (if applicable)
Renal transplant history  (if applicable)
■Date of transplant
■Date of transplant failure
■ Current immunosuppression
Determine cirrhosis status as defined in Section 4.1.
Record l iver biops y or Fibroscan r esults (if applicable)
If the presence of cirrhosis is determined, then appropriate diagnostic imaging should be 
performed or confirmed to have been performed within 6months of screening to exclude 
the presence of HCC
Obtain details of concomitant medicat ions
Perform 12- lead ECG
Complete phy sical examination including vital signs (resting blood pressure, pulse, 
respi ratoryrate and temperature) , body  weight, and height
Pregnancy  prevention counseling
Obtain blood samples fortests as listed in Section 6.9.1:
Hematology
Chemistry
Coagulation tests
HCV RNA
Determination of HCV viral genot y
peand subtype
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 42 02March 2017HCV antibody , HIV 1/2 antibody , HBVsurface antigen (HBsAg), HBV core antibod y 
(HBcAb), and HBV surface antibody  (HBsAb)
HbA1c
IL28B genoty ping
Serum β -hCG pregnancy test for females of childbearing potential on ly
HIV- 1 RNA and CD4 c ell count will on ly be collected and ana lyzed for HIV co-infected 
subjects
Fibrotest®
Serum drug screen
Record an y serious adverse events and all adverse event srelated to protocol mandated 
procedures occurring after signing of the consent form.
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic within 28 day s after screening for enrollmen tinto the study .The screening window can be 
extended up to 42 da ys for extenuating circumstances with Sponsor approval .
Retests of Screening labs are permitted only if the initial exclusionary  value was either due to a
sample processing error or due to extenuating circumstances such as intercurrent illness.
From the time of obtaining informed consent through the first administration of investigational 
medicinal product, record all serious adverse events (SAEs), as well as any adverse events 
related to protocol- manda ted procedures on the adverse event s case report form (CRF/eCRF). 
All other untoward medical occurrences observed during the screening period, including 
exacerbation or changes in medical history are to be captured on the medical history  CRF/eCRF. 
See S ection7Adverse Events and Toxicity  Management for additional details.
Day 1 Assessments 6.2.
The following baseline tests and procedures must be completed prior to enrol lment and
dosing/dispensation ofstudydrug:
Confirm eligibility (SeeSections 4.1&4.2)
Perform complete p hysical examination, including vital signs and body weight
Perform 12- lead ECG (prior to study  drug administration)
Assessment of AEs and concomitant medications
Pregnancy  prevention counselling 
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 43 02March 2017Subject completes Health Related Quality of Life Questionnaire: SF -36, CLDQ -HCV, 
FACIT -F, and WPAI
Obtain blood samples for:
Hematology
Chemistry
Coagulation tests
HCV RNA
Viral sequencing /phenoty ping
Serum β -hCG pregnancy test for females of childbearing potential on ly
HIV- 1 RNA and CD4 cell count will on ly be collected and ana lyzed for co-infected 
subjects
HBV DNA (only in subjects who are HBcAb+ at Screening)

Pharmacogenomic sample (for subjects who have consented). M ay be collected at a 
subsequent visit if necessary .
StudyDrug Administration
Dispense study drug as directed b ytheIWRS
Instruct the subject on the packaging, storage and administration of the study drugs
Observe the subject taking the first dose of studydrug and record the time of first dose
and whether it was taken with or without food.
Treatment Assessments 6.3.
6.3.1. Week 2 (± 3 days) : Group 1, 2 ,and 3
The following procedures/assessments are to be completed at the end of Week 2:
Obtain vital signs
Assessment of AEs and concomitant medications
CCI
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 44 02March 2017Obtain blood samples for:
Hematology
Chemistry
HCV RNA
Viral sequencing /phenoty ping
Sparse PK sample
Assess adherence with study drug dosing regimen including pill count
6.3.2. Week 4 (± 3 days ): Group 1, 2 ,and 3
The following procedures/assessments are to be completed at the end of Week 4:
Obtain vital signs
Assessment of AEs and concomitant medications
Conduct pregnancy  prevention counselling
Obtain blood samples for:
Hematology
Chemistry
HCV RNA
Viral sequencing /phenoty ping
Sparse PK sample
Serum β -hCG pregnancy test for females of childbearing potential on l
y
HIV- 1 RNA and CD4 cell count will on ly be collected and ana lyzed for HIV co - infected 
subjects
HBV DNA (only in subjects who are HBcAb+ at Screening)
Assess adherence with study drug dosing regimen including pill count
Dispense study  drug as directed b y the IWRS
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 45 02March 20176.3.3. Week 6 (± 3 days ): Group 1, 2 ,and 3
The following procedures/assessments are to be completed at the end of Week 6:
Obtain vital signs 
Assessment of AEs and concomitant medications
Obtain blood samples for:
Hematology
Chemistry
HCV RNA
Viral sequencing /phenoty ping
Sparse PK sample
Intensive PK (for subjects who have consented)
Hemodialy sis PK (for subjects who have consented)
Assess adherence with study drug d osing regimen including pill count
6.3.4. Week 8 (± 3 days) :Group 2 and 3 (For Group 1 Week 8, see End of 
Treatment Visit)
The following procedures/assessments are to be completed at the end of Week 8for 
Groups 2and 3 onl y
:
Obtain vital signs 
Assessment of AEs and concomitant medications
Conduct pregnancy  prevention counselling
Obtain blood samples for:
Hematology
Chemistry
HCV RNA
Viral sequencing /phenoty ping
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 46 02March 2017Sparse PK sample
Serum β -hCG pregnancy test for females of childbearing potential on ly
HIV- 1 RNA and CD4 cell count will on ly be collected and ana lyzed for HIV co - infected 
subjects
HBV DNA (only in subjects who are HBcAb+ at Screening)
Intensive PK (for subjects who have consented)
Hemodialy sis PK (for subjects who have consented)
Assess adherence with study drug dosing regimen including pill count
Dispense study  drug as directed b y the IWRS 
6.3.5. Week 12, 16
,and 20 (± 3 days): Group 3 (For Group 2 Week 12, see End of 
Treatment Visit)
The following procedures/assessments are to be completed at the end of Week 12, 16, and 20 for 
Group 3 only :
Obtain vital signs 
Assessment of AEs and concomitant medications
Conduct pregnancy  prevention counselling
Obtain blood samples for:
Hematology
Chemistry
HCV RNA
Viral sequencing /phenoty ping
H
IV-1 RNA and CD4 cell count will onl y be collected and ana lyzed for HIV co-infected 
subjects
HBV DNA (only in subjects who are HBcAb+ at Screening )
Sparse PK sample
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 47 02March 2017Serum β -hCG pregnancy test for females of childbearing potential on ly
Week 12 only : Intensive PK (for subjects who have consented)
Week 12 only : Hemodialy sis PK (for subjects who have consented)
Assess adherence with study drug dosing regimen including pill count
Dispense study  drug as directed b y the IWRS
6.3.6. End of Treatment Visit: Group 1 Week 8 (± 3 days), Group 2 Week 12 
(±3days), Group 3 
Week 24 (± 3 days) or Early Termination (ET)
The following procedures/assessments are to be completed at the end of Week 24/ET:
Perform complete ph ysical examination , including vital signs and bod y weight
Perform 12
-lead ECG
Assessment of AEs and concomitant medications
Pregnancy  prevention counseling
Subject completes Health Related Quality  of Life Questionnaire: SF -36, CLDQ -HCV, 
FACIT -F, and WPAI
Obtain blood samples for:
Hematology
Chemistry
Coagulation tests
HCV RNA
Viral sequencing /phenoty ping
HIV- 1 RNA and CD4 cell count will on ly be collected and ana lyzed for HIV co- infected 
subjects
HBV DNA (only in subjects who are HBcAb+ at Screening )
Sparse PKsample
Serum β -hCG pregnancy test for females of childbearing potential on ly
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 48 02March 2017
Group 1, Week 8: Intensive PK (fo r subjects who have consented)
Group 1, Week 8: Hemodialy sis PK (for subjects who have consented)
Group 2, Week12: Intensive PK (for subjects who have consente d)
Group 2, Week 12: Hemodialy sis PK (for subjects who have consented)
Assess adherence with study  drug dosing regimen including pill count
Subjects should return all bottles of study drug 
Post-treatment Assessments 6.4.
6.4.1. Posttreatment Wee k 4Visit (±5 days) : Group 1, Group 2 ,andGroup 3
The following procedures/assessments are to be completed at Posttreatment Week 4:
Perform complete ph ysical examination , including vital signs
Assess mentofAEs andconcomitant medications
Pregnancy prevention counselling
Subject completes Health Related Quality of Life Questionnaire: SF -36, CLDQ -HCV, 
FACIT -F, and WPAI
Obtain blood samples fo r:
Hem atology
Chemistry
HCV RNA
Viral sequencing /phenoty ping
HIV- 1 RNA and CD4 cell count will on ly be collected and ana lyzed for HIV co-infected 
subjects
HBV DNA (only in subjects who are HBcAb+ at Screening)
Serum β -hCG pregnancy test for females of childbearing potential on ly
CCI
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 49 02March 20176.4.2. Posttreatment Week 12Visit (±5 days) : Group 1, Group 2 and Group 3
The following procedures/assessments are to be completed at Posttreatment Week12 and 24:
Perform complete ph ysical examination , including vital signs
Assessment of S AEs 
Subject completes Health Related Quality  of Life Questionnaire: SF -36, CLDQ -HCV, 
FACI T-F, and WPAI 
Obtain blood samples fo r:
Hematology
Chemistry
HCV RNA
HBV DNA (only in subjects who are HBcAb+ at Screening )
Viral sequencing /phenoty ping
6.4.3. Posttreatment Week 24 Visit (±5 Days): Only for Subjects who Achieved 
SVR12
The following procedures/assessments are to be completed at Posttreatment Week 24:
Perform complete ph ysical examination , including vital signs
Assessment of S AEs 
Obtain blood samples fo r:
Hematology
Chemistry
HCV RNA
HBV DNA (only in subjects who are HBcAb+ at Screening)
Viral sequencing/phenotyping
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 50 02March 2017Early Termination (ET) 6.5.
For subjects who have completed an ET visit, the posttreatment Week 4 and12 follow -up visits 
will be scheduled after last dose of a ny of the study  drug. Subjects who achieve SVR12 
(HCV RNA < LLOQ at posttreatment Week 12) will complete the posttreatment Week 24 visit.
When medical ly feasible, the medical monitor must be consulted prior to subject discontinuation.
If a subject discontinues study  dosing (for example, as a result of an AE), every  attempt should 
be made to keep the subject in the study and continue to perform the required study -related 
follow -up and procedures (see Section 3.4, Criteria for Discontinuation of Study  Treatment ). If 
this is not possible or acceptable to the subject or investigator, the subject may  be withdrawn 
from the study .
Unscheduled Visit 6.6.
A subject should attend an unscheduled visit if requested by the Sponsor or the Investigator . 
Theassessments are at the Investigator’s discretion as clinically indicated, but the Investigator 
should, at a minimum, collect AE and concomitant medication information. At all unscheduled 
visits initiated for the purpose of confirming HCV or HIV virologic failur eanda sample for 
HCV or HIV viral sequencing/pheno typing must be collected .
End of Study 6.7.
The end of stud y will occur at the posttreatment Week 24 visit .
Discontinuation from study  drug dosing and discontinuation from the overall study , including the
Posttreatment period, will be collected as two separate events .
Post Study Care 6.8.
Nopost study ongoing care will be provided.
Procedures and Specifications 6.9.
6.9.1. Clinical Laboratory Analytes
Hematology : Hem atocrit, hemoglobin (Hb), platelet count, red blood cell count (RBC),
white blood cellcount (WBC) with differential (absolute and percentage) 
including l ymphocy tes, monoc ytes, neutrophils, eosinophils, basophils, 
reticulocy te count and mean corpuscular volu me (MCV ).
Coagulation: INR, Prothrombin time(PT), Activated partia lthromboplastin time
(APTT)
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 51 02March 2017Chemistry : Alanine aminotransferase (ALT/SGPT), asparta te aminotransferase 
(AST/SGOT), albumin, alkaline phosphatase, creatinine, total bilirubin ,
direct bilirubin; glucose, potassium, and sodium. Fibrotest®will be done at 
screening onl y.
Virological Tests: Serologies for HCV and HBV (HBsAg, HBsAb, and HBcAb) .HBV DNA 
(only  in subjects who are HBcAb+ at Screening). Serology  testing for HIV 
(including reflex testing as necessary ), HCV RNA will be measured using 
the COBAS®AmpliPrep/COBAS®TaqMan®HCV Test, v2.0 for Use 
with the High Pure S ystem, HCV genot ype and subty pe will be 
determined using the Siemens VERSANT® HCV Genoty pe, INN
O-LiPA 
2.0 Assay . HIV-1 RNA will be measured using the AmpliPrep/COBAS®
TaqMan®HIV
-1 Test, v2.0. If HIV -1 virologic rebound is confirmed, 
HIV-1 genot ype/phenot ype will be determined using the PhenoSense ™
Integrase HIV, GeneSeq™ I ntegrase HIV, PhenoSense™ HIV, GenoSure 
MG, GeneSeq™ HIV, and PhenoSense GT™ . 
Gilead reserves the right to use alternate a ssays for HCV RNA, HIV RNA, 
HCV genot ype, and HIV -1 geno type/phenot ype should the above assa ys 
become unav ailable or the results are not definitive.
IL28B genoty pe will be determined by  polymerase chain reaction (PCR) 
amplification of the SNP, rs12979860, with sequence specific forward and 
reverse primers and allele specific fluorescently  labeled TaqMan®MGB 
probes. Gilead reserves the rights to use alternate assay s for IL28B 
determination should the above assay  become unavailable.
Pregnancy Tests: Serum β-hCG
Additional Tests : Serum drug screen (foramphetamines, cocaine, methadone, opiates), 
HbA1c ,CD4 T- lymphocy te (absolute c ount and % )
6.9.2. Medical History
Medical history  including details regarding illnesses and allergies, date(s) of onset, and whether
condition(s) is currentl y ongoing, and medication history  will be collected on all subjects during
screening. Obtain HCV treatment , renal dial ysis, and kidney  transplant history  as per Section 4.
6.9.3. Complete Physical Examination
A complete ph ysical examinatio n must include source documentation of general appearance, and
the following bod y systems: Head, neck and thy roid; ey es, ears, nose, throat, mouth and tongue;
chest (excluding breasts); respiratory ; cardiovascular; ly mph nodes, abdomen; skin, hair, nails;
musculoskeletal; neurological.
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 52 02March 20176.9.4. Height & Weight Measurement
Height will be collected at Screening. Weight measurement will be collected at Screening, Day 1 
and Week 8 (Group 1), Week 12 (Group 2), Week 24 (Group 3) or ET visits
6.9.5. Vital Signs
Assessment of vital signs will include measurement of resting blood pressure, pulse, respiratory  
rate, and temperature and will be conducted pre-dose as outlined in Appendix Table 1, 
Appendix Table 2andAppendix Table 3.
Blood pressure will be measured using the 
following standardized process:
Subject should sit for  5 minutes with feet flat on the floor and measurement arm supported 
so that the midpoint of the manometer cuff is at heart level;
Use a mercury sphygmomanometer or automatic blood pressure device with an appropriately  
sized cuff with the bladder centered over the brachial arter y;
Measure and record the blood pressure to the nearest 2 mmHg mark on the manometer or to 
the nearest whole number on an automatic device.
6.9.6. Body Mass Index (BMI)
BMI is calculated b y the following equation :
BMI=weight (pounds) or Weight in kilograms
(height in inches)2(height in meters)2
6.9.7. 12 -Lead ECG
Subjects will be required to rest in a supine position for ≥ 5 m inutes prior tomaking a recording.
The Investigator (orqualified designee) should review the ECG traces recorded in real time for 
clinically significant abnor malities. End of treatment or ET results will be compared to the 
subject’s Day  1 ECG as part of routine safety monitoring.
6.9.8. Health Related Quality of Life (HRQoL)
Health Related Quality  of L ife survey s (HRQoL) included in this study  are the SF -36, Chronic 
Liver Disease Questionnaire (CLDQ -HCV), Fatigue Index (FACIT -F), and Work Productivity  
and Activity  Impairment Questionnaire: Hepatitis C, v2.0 (WPAI : Hep atitis C) which will be 
completed bysubjects atDay 1, and at the on -treatment Week 8 (Group 1), Week 1 2 (Group 2), 
Week 24 (Group 3) visits, ET (if applicabl e), and posttreatment Week 12 visit.
The Health Related Quality  of Life survey s (HRQoL) will only be administered to subjects if
available at Day  1. The subject should read the questionnaire b y himself/herself and record the
answers b y himself/herself.
LDV/SOF 
Protoco l GS-US-337 -4063 
Gilead Sciences , Inc. 
6.9.9. Viral Sequencin g/Pheno typing (Archi ve) Final 
Amendment 3.0 
Plasma samples will be collected at Day 1 and each subseq uent visit for HCV or HIV viral 
seque nce and phen otyping analysis. At any unsched uled visit initiated for the p urpose of 
confinnin g HCV virologic breakthrough, H CV viral seque ncing/ phenotype plasma sample must 
also be collected. Unused samples may be archived. 
Detai ls regarding the collection , process ing, and s hipping of samples will be included in the lab 
manual. 
6.9.10. Sparse PK Sample 
Sparse PK blood samples will be collected for all subjects at each on-treatme nt visit and arch ived 
for PK analysis ofLDV and SOF (and m etabo lites). 
The exact time of the dose taken prior to collection of the PK sample, the exact time the PK 
sample is draw n, the exact time of comple tion of last dialysis, and the type of dialysis (perito neal 
or hemodialysis) will be recorded in source documents and eCRFs. 
Detai ls regarding the collection , process ing, and s hipping of samples will be included in the lab 
manual. 
6.9.11. 
I 
6.9.12. 
CONFIDENTIAL Page 53 02 March 2017 
LDV/SOF 
Protocol GS-US-337 -4063 
Gilead Sciences , Inc. 
6.9.13. Pharmacogenomic s Testing Final 
Amendment 3.0 
For subjects who p rovide speci fic and separate consent to paiiicipate will allow the Spon sor to 
obtain and test a subject's blood sample taken on B aseline/Day 1 for phannacoge nomics 
discove 1 y researc h. If not obtained at Baseline/Da 1, the sam le ma be drawn at an time - Y· 
6.9.14. Archi ve sample 
6.9.15. Pregnanc y Testing 
All females of childbea ring potential will have sernm pregnancy testing eve1 y 4 weeks dming the 
dosing period and 30 days after last dose of LDV/SOF, or the last visit of the study , whichever 
comes last. 
CONFIDENTIAL Page 54 02 March 2017 
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 55 02March 20177. ADVERSE EVENTS AND T OXICITY  MANAGEMENT
Definition sof Adverse Events , Adverse Reactions, and Serious Adverse 7.1.
Events
7.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study  subject 
administered a medicinal product ,which does not necessarily  have a causal relationship with th e
treatment. An AE can therefore be an y unfavorable and /orunintended sign, symptom, or disease 
temporally  associated with the use of a medicinal product, whether or not considered re lated to 
the medicinal product. AEs may  also include pre -or post-treatment complications that occur as a 
result of protocol specified procedures, la ck of efficacy , overdose ,drug abuse/misuse reports , or 
occupational exposure .Preexisting events that increase in severit y or change in nature during or 
as a consequence of participation in the clinical study will also be considered AEs.
An AE does not in clude the following:
Medical or surgical procedures such as surgery , endoscopy ,tooth extraction, andtransfusion .
The condition that ledto the procedure may be an adverse event and must be reported.
Pre-existing diseases ,conditions ,or laboratory  abnorm alities present or detected before the 
screening visit that donot worsen
Situations where an untoward medical occurrence has not occurred (e.g. ,hospitalization for 
elective surgery , social and/or convenience admissions)
Overdose without clinical sequelae (see Section 7.5.1 )
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. I t is considered to be pre -existing and should be documented on the medical history  
CRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as anevent that, at any dose, results in the following :
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” ref ers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospitalization or prolongation of existing hospitalization
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 56 02March 2017Persistent or significant disability /incapacit y
A congenital anomal y/birth defect
A medicall y important event or reaction: such events may  not be immediately  
life-threatening or result in death or hospitalization but may  jeopardize the subject or may  
require intervention to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of m edically  important e vents include inten sive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; anddevelopment of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contami nated medicinal 
product will be considered a 
medicall y important e vent and subject to expedited reporting 
requirements.
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (e .g., clinical chemistry , hematology , and urinaly sis ) that 
require medical or surgical intervention or lead to IMP interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (e.g., electrocardiogram, x -rays, vital signs) that are 
associated with signs and/or sy mptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections 7.1.1 and7.1.2. If the laboratory  
abnormality
 is part of a sy ndrome, record the s yndrome or diagnosis (e .g., anemia), not the 
laboratory  result (i .e., decreased hemoglobin). Assessment of Adverse E vents and Serious 
Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality  and severity , and for final review and confirmation of accuracy  of event information 
and assessments.
7.1.4. Assessment of Causa lity for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing t he relationship to IMP
therap y using clinical judgment and the following considerations:
No:Evidence exists that the adverse event has an etiology  other than the IMP. For SAEs, an 
alternative causality  must be provided (e .g., pre - existing condition, underl ying disease, 
intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by the
investigational medicinal product.
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 57 02March 2017It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of adverse event reporting. 
The relationship to study  procedures (e .g., invasive procedures such as venipunc ture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the study  procedure.
Yes: The adverse event occurred as a result of protocol procedures ,(e.g.,venipun cture ).
7.1.5. Assessment of Severity
Theseverit ygrading ofAEs willbeassessed asGrade 1, 2, 3, or 4 using the GSI Grading Scale 
for Severit y of Adverse Events and Laboratory Abnormalities (Appendix 3). For AEs associated 
with laboratory  abnormalities, the event should be graded on the basis of the clinical severity in
thecontext of the underlying conditions; this may or may not be in agree ment with the grading 
of the laboratory  abnormality .
Investigator Requirements and Instructions for Reporting Adverse Events 7.2.
and Serious Adverse Events to Gilead
7.2.1. Requirements for collection prior to study drug initiation:
After informed consent, but prior to initiation of study medication, the following t ypes of events 
should be reported on the case report form (CRF/eCRF): all SAEs ,and all adverse events related 
to protocol -mandated procedures.
7.2.2. Adverse Events
Following initiation of study  medication, collect a ll AEs, regardless of cause or relationship, 
until 30-days after last administration of study  IMP and report to the CRF/eCRF database as 
instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
Gilead Sciences may  request that certain AEs be followed bey ond the protocol defined follow up 
period .
7.2.3. Serious Adverse Events
All SAEs , regardless of cause or relationship, that occur after the subject first consents to 
participate in the study (ie, signing the informed consent) and throughout the duration of the 
study , including the protocol -required post treatment follow -up period, mus t be reported to the 
CRF/eCRF database and Gilead Drug Safet y and Public Health (DSPH) as instructed. This also 
includes an y SAEs resulting from protocol -associated procedures performed after informed 
consent is signed.
LDV/ SOF 
Protocol GS-US-337-4063 
Gilead Sciences , Inc. Final 
Amendment 3.0 
Investigators are n ot obligated to actively seek SAEs after the protocol defined follow up period, 
howeve r, if the investigato r learns of any SAEs that occur after study paiiicipatio n has concluded 
and the event is deemed releva nt to the u se ofIMP, he/she sho uld pro mptly document and r epo1i 
the event to Gilead DSPH. 
• All AEs and SAEs will be recorde d in the eCRF database within the timelines outlin ed in the 
eCRF completion guideline. 
7.2.4. Electronic Seriou s Adver se Event ( eSAE ) Reporting Proce ss 
Site perso nnel must record all SAE data in the eCRF database and tr ansmit the SAE infonnation 
to Gi lead DSPH within 24 hours of the investigato r 's know ledge of the event. Detai led 
instrnctions can be found in the eCRF completion guide lines . 
If it is not possib le to record and submit the SAE info1mation electro nically, beca use the eCRF 
database cannot be accessed or is not available (inclu ding at study staii) , record the SAE on the 
paper serious adverse event repo1 i fonn and sub mit by e-mail or fax within 24 hours of the 
investigato r's knowle dge of the event to: 
GileadDS PH Fax: 
E-mail: PPD 
PPU 
As soon as it is possib le to do so, any SAE repo1 ied via paper must be transcribed into the eCRF 
Database acco rding to instructions in the eCRF completion guidelines. 
If an SAE has been repo1ied via a paper f 01m because the eCRF database has been locked, no 
fmther actio n is necessaiy. 
For fatal or life-threatening events, copies of hospital case repo1is, autopsy repo1is, and other 
documents are al so to be submitted by e-mail or fax when requested and applicable. 
Transmission of such documents sho uld occur without perso nal subject identificatio n, 
maintaining the ti·aceabi lity of a document to th e subj ect identifiers. 
Additio nal infonnatio n may be requested to ensure the timely completion of accurate safety 
repo1is. 
Any medicat ions n ecessa1y for ti·eatinent of the S AE must be recorded onto the concomitant 
medica tion section of the subject's CRF /eCRF and the event descriptio n sectio n of the SAE 
f01m . 
7.3. Gilead Reporting Requirement s 
Depending on rel evant local legislation or regulations, including the app licable US FDA Code of 
Fede ral Regulations, the EU Clinical Trials Directive (2001/20/EC) and releva nt updates, and 
other countiy -specific legislation or regulatio ns, Gilead may be required to exped ite to 
worldwide regulato1 y agencies reports of SAEs, serious ad verse drng reactio ns (SAD Rs), or 
CONF IDENTIAL Page 58 02 March 2017 
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 59 02March 2017suspected unexpected serious adverse reactions (SUSARs). In accordance with the EU Clinical 
Trials Directive (2001/20/EC), Gilead or a specified designee will notify  worldwide regulatory  
agencies and the relevant IECin concerned Member States of applicable SUSARs as outlined in 
current regulations.
Assessment of e xpectedness forSAEs will be determined by  Gilead using reference safety  
information specified in the investigator’s brochure or relevant local label as applicable . 
All investigators will receive a safet y letter notifying them of relevant SUSAR reports associated 
with any  study  IMP. The investigator should notify  the IRB or IEC of SUSAR reports as soon as 
is practical, where this is required b y local regulatory agencies , and in accordance with the local 
institutional policy . 
Toxicity Management 7.4.
7.4.1. Subject Stopping Rules
See Section 3.4for individual subject stopping rules .
Special Situations Reports 7.5.
7.5.1. Definitions of Special Situations
Special situation reports includ e all reports of medication error, abuse, misuse, overdose , reports 
of adverse events associated with product complaints ,occupational exposure with an AE,
pregnan cy reports regardless of an associated AE , and an AE in an infant following exposure 
from breastfeeding .
Medication error is an y unintentional error in the prescribing, dispensing ,or administration of a 
medicinal product while in the control of the health care provider , subject, or consumer.
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product b y a 
subject.
Misuse is defined as an y intentional andinappropriate useof a medicinal p roduct that is not in 
accordance wit h the protocol instructions or the local prescribing information .
An overdose is defined as an accidental or intentional administration of a quantity of a medicinal 
product given per administration or cumulatively which is above the maximum recommended 
dose as per protocol or in the product labelling (as it applies to the daily dose of the subje ct in 
question). In cases of a discrepancy in drug accountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy  except i n cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.
LDV/SOF 
Protoco l GS-US-337 -4063 
Gilead Sciences , Inc. 
7.5.2. 
7.5.2.1. Instruction s for Reporting Special Situation s 
Instiuctio ns for Repo1i ing Pregna ncies Final 
Amendment 3.0 
The investigato r shou ld repo1 i preg nanci es in female study subjects that are identified after 
initiation of study m edicatio n and throughout the study, including the post study drng follow-up 
period, to Gilead DSPH using the pregna ncy repo1i fo1 m within 24 hours of beco ming aware of 
the pr egnancy. 
Refe r to Section 7 .2 and the eCRF completion guidelines for full instiuct ions on the mechanism 
of preg nancy repo1i ing. 
The pr egnancy itself is not considered an AE nor is an induced elective abort ion to te1minate a 
pregna ncy without medical reaso ns. 
Any premature te1mination of pregnancy (e.g. , a spon taneous abo1iion, an induced therape utic 
abo1iion due to complicat ions or other medical reaso ns) must be repo1ied within 24 hours as an 
SAE . The underlying medical reaso n for this procedure should be recorded as the AE te1m. 
A spon taneo us abo1iio n is always considered to be an SAE and will be repo1ied as descr ibed in 
Sectio ns 7 .1.1 and 7 .1.2. Fmt hen nore , any SAE occu ning as an adverse pregna ncy outcome post 
study must be repo1ied to Gilead DSPH. 
The subject shou ld receive approp riate monitoring and care until the conclusion of the 
preg nancy. The outco me sh ould be repo1ied to Gilea d DSPH using the preg nancy outcome repo1i 
fo1m. If the end of the pregna ncy occurs after the study has been complete d, the ou tcome should 
be repo1ied direc tly to Gilead DSPH. 
Gilead DSPH contact infonnation is as follows: 
Emai l: IPIPD 
Fax: IPIPD 
Pregnancies of female paiiners of male study su bjects exposed to Gilead or other study diugs 
must also be repo1ied and releva nt info1matio n shou ld be submitted to Gilead DSPH us ing the 
pregna ncy and pregnancy outcome fo1ms within 24 h ours. Monitoring of the su bject shou ld 
continue until the conclusion of the pr egna ncy. If the e nd of the pregnancy occurs after the study 
has been completed, the outcome shou ld be repo1ied directly to Gilead DSPH. 
Emai l: IPIPD 
Fax: IPIPD 
Refe r to Appe ndix 4 for Pregna ncy Precautio ns, D efinition for Female of Childbeai ·ing Pote ntial, 
and Contl'aceptive Requirements. 
CONFIDENTIAL Page 60 02 March 2017 
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 61 02March 20177.5.2.2. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to Gilead DSPH within 24 hours of the investigator becoming aware of the situation. 
These reports must consist of situations that involve study  IMPand/or Gilead concomitant 
medications, but do not apply to non-Gilead concomitant medicat ions. 
Special situations involving non-Gilead concomitant medications donot need to be reported on 
the special situations report form; however, for special situations that result in AEs due to a 
non-Gilead concomitant medication , the AE should be reporte d on the AE form . 
Any inappropriate use of concomitant medications prohibited by  this protocol should not be 
reported as “misuse,” but may  be more appropriately  documented as a protocol deviation.
Refer to S ection 7.5and the eCRF completion guidelines for full instructions on the mechanism 
of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the sy mptoms and 
signs, clinical management, and outcome will be reported, when available.
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 62 02March 20178. STATISTICAL  CONSIDER ATIONS
Analysis Objectives and Endpoints 8.1.
8.1.1. Analysis Objectives
The primary objectives of this study are as follows :
To evaluate the antiviral efficacy  of treatment with ledipasvir/sofosbuvir (LDV/SOF) for 
8,12 or 24 weeks in subjects as measured b y the proportion of subjects with sustained viral 
response 12 weeks after cessation of treatment (SVR12)
To evaluate the safet y and tolerability  of each treatment regimen
The secondary objectives of this study are as follows: 
To determine the proportion of subje cts who attain SVR at 4 and 24 weeks after cessation of 
each stud y treatment regimen (SVR4 and SVR24)
To evaluate the proportion of subjects with virologic failure
To evaluate the kinetics of circulating HCV RNA during treatment and after cessation of 
treatment 
To evaluate the emergence of viral resistance to LDV and SOF during treatment and after 
cessation of treatment
To evaluate the stead y-state pharmaco kinetics of LDV and SOF and its metabolites in 
subjects who are on dialysis for ESRD
The exploratory objective sof this study are:
8.1.2. Primary Endpoint
The primary  end point is SVR12 (HCV RNA < LLOQ 12 weeks after cessation of treatment) in 
the Full Anal ysis Set (FAS) population .
The primary  safet y endpoint is any AE that led to permanent discontinuation of study drug.
CCI
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 63 02March 20178.1.3. Secondary Endpoint
Secondary  endpoints include the following:
The proportion of subjects with HCV RNA < LLOQ at 4 and 24 weeks after cessation of 
treatment (SVR4 and SVR24)
The proportion of subjects with HCV RNA < LLOQ on treatment
HCV RNA change fr om Baseline/Day  1
The proportion of subjects with virologic failure
The proportion of subjects who develop viral resistance to LDV and SOF during treatment 
and after cessation of treatment
Thestead y-state pharmacokinetics of LDV and SOF and its metabolite s
8.1.4. Other Endpoints of Interest
Additional efficacy  evaluations may  include effect of treatment with LDV/SOF on HRQoL 
endpoints .
Analysis Conventions 8.2.
All individual subject data will be listed as measured. All statistical summaries and anal yses will
be performed using SAS®software (SAS Institute, Cary , North Carolina, USA).
The study  drugs in this study  are LDV /SOF . Last dose of study  drug will be used in the 
definition of treatment emergent AEs and laboratory  abnormalities as well as the efficacy  
endpoints of SVR at various posttreatment time points.
8.2.1. Analysis Sets
8.2.1.1. Efficacy
The primary  anal ysis set for efficacy  anal ysis will be the FAS, which includes all enrolled 
subjects who took at least 1 dose of study  drug.
8.2.1.2. Safety
The primary  anal ysis set for s afety  anal yses will be the Safet y Analysis Set, which includes all 
subjects who took at least 1 dose of study  drug.
Treatment -emergent data will be anal yzed and defined as data collected from the first dose date 
of the study  drug through the last dose date of study  drug plus 30 day s.
LDV /SOF 
Protocol GS-US-337-4063 
Gilead Sciences , Inc. 
8.2.1.3. Phaima cokineti cs Final 
Amendment 3.0 
The PK Analysis Set include s all subjects who took at least 1 dose of the study drng and have at 
least 1 no nmissing postdose concentrati on value for the conespo nding analyte in plasma. The 
analytes of intere st may include LDV and SOF (and its metab olites GS-566500 and GS-331007) . 
8.2.1.3.1. 
8.2.1.3.2. 
8.3. Data Handling Conventions 
Missing data can have an impa ct upon the interpr etation of the trial data. Other than the 
endpoints discussed below , values for missing data. will not be imputed. 
For the analyses of categorical HCV RNA data, missing posttrea tment HCV RNA data will have 
the missing data. imputed . Missing on-tre atment HCV RNA will have the missing data imputed 
up to the time of the last dose. 
If a data point is missing and is preceded and followed in time by values that ai· e "< LLOQ target 
not detected (TND)", then the missing data point will be set to"< LLOQ TND". If a data point is 
missing and preceded and followed by values that ai·e "< LLOQ detected ", or preceded by 
"< LLOQ detected" and followed by"< LLOQ TND ", or preceded by"< LLOQ TND " and 
followed by"< LLOQ detected", then the missing value will be set to"< LLOQ detected" . In 
these situations the data point will be te1med a bracketed succe ss; othe1wise, the data point will 
be te1med a bracketed failme (i.e.,~ LLOQ detected) . If a data point is missing and is not 
bracketed, the missing data po int will also be te1med a failure (i.e.,~ LLOQ detected) except for 
SVR24 , which will be imput ed according to the SVR12 status. Succe ss for SVR12 who have no 
fmth er HCV RNA measmem ents collected will be counted as a success for SVR24 due to the 
high conelation betwee n these 2 endpoints. 
CONF IDENTIAL Page 64 02 March 2017 
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 65 02March 2017Where appropriate, safety  data for subjects who did not complete the study will be included in 
summary  statistics. For example,
If a subject took at least 1 dose of study  drug, the subject will be included in a summary  of 
AEs according to the treatment received; otherwise, if the subject is not dosed, then they  will 
be excluded from the summary .
If safety  laboratory  results for a subject are missing for any  reason at a time point, the subjec t 
will be excluded from the calculation of the summary  statistics for that time point. I f the 
subject is missing a predose value, then the subject will be excluded from the calculation of 
the summary  statistics for the predose value and the change from pre dose values.
Values for missing safety laboratory  data will not be imputed; however, a missing 
Baseline/Day 1 result will be replaced with a screening result, if available. If no pretreatment 
laboratory  value is available, the Baseline/Day  1 value will be assumed to be normal 
(i.e., nograde [Grade 0]) for the summary  of graded laboratory  abnormalities.
Values for missing vital signs data will not be imputed; however, a missing Baseline/Day 1 result 
will be replaced with a screening result, if available.
HCV RNA values below the LLOQ for the assay  will be set to the lower limit minus 1 for the 
calculation of summary  statistics for the actual HCV RNA values and the change from baseline 
values by  study  visit. The reported values will be provided in the HCV RNA listing.
For selected anal yses of earl y time point data, HCV RNA data (IU/mL) may be transformed to 
the logarithmic (base 10) scale (log 10IU/mL).
For PK plasma/blood concentrations and anal ysis of PK parameters natural logarithmic 
transformation will be used. For the intensive PK samples, plasma concentration values that are 
below the lower limit of quantitation (BLQ) will be presented as “BLQ” in the concentration 
data listing. Values that are BLQ will be treated as 0 at predose time points, and one -halfthe 
value of the lower limit of quantitation (LLOQ) at postbaseline time points, where LLOQ is 
corrected for the dilution factor (i.e., reported LLOQ/dilution factor) for determination of 
summary  and order statistics. 
For the presentation of summary  and order statistics, if at least 1 subject has a concentration 
value of BLQ for the time point, then the minimum value will be display ed as “BLQ” .If more 
than 25% of the subjects have a concentration data value of BLQ for a given time point, then the 
minimum and Q1 values will be displayed as “BLQ” .If more than 50% of the subjects have a 
concentration data value of BLQ for a given time point, then the minimum, Q1, and median 
values will be display ed as “BLQ” .If more than 75% of the subjects have a concentration data 
value of BLQ for a given time point, then the minimum, Q1, median, and Q3 values will be 
display ed as “BLQ”. If all subjects have concentration data values of BLQ for a given time point, 
then all order statistics (minimum, Q1, median, Q3, and max imum) and summary  statistics will 
be display ed as “BLQ” .
LDV/ SOF 
Protocol GS-US-337-4063 
Gilead Sciences , Inc. 
8.4. Demographic Data and Baseline Characteri stics Final 
Amendment 3.0 
Dem ographic and basel ine measuremen ts will be summ arized using standard descr iptive 
methods by ti·eatment group and overall. 
Dem ographic summ aries will include sex, self-identified race/ethnicity , and age. 
Baseline data will inclu de a summ aiy of body mass index, HCV RNA level (logl 0 IU/mL), 
genotype and s ubtype ofHCV infec tion, IL28B genotype , and additional endpoint as necessaiy. 
8.5. Efficac y Anal ysis 
8.5.1. Primary Anal ysis 
The primaiy endpoint is SVR 12 in the Fu ll Analysis Set (FAS) population. 
In the primaiy efficacy analysis , the po int estimate and the 2-sided 95% exact confidence 
interval of SVR12 rate will be provided for the overa ll FAS population and by ti·eatment group. 
8.5.2. Secondary Anal yses 
The propo 1tion of subjects with H CV RNA below the LL OQ over time (inclu ding SVR 
endpoints) will be presented by ti·eatment group in tabulai· and grap hical fonn. 
Descriptive summai ·ies and listings will be provide d for additio nal efficacy evaluatio ns of the 
propo1tio n of subjects who expe rience virologic failure, HCV RNA actual values and chan ge 
from base line. 
Details on efficacy analyses will be described in the sta tistical analysis plan . 
8.6. Safety Anal ysis 
Safety will be evaluated by assess ment of clinical laborato1y tests (including HIV- 1 RNA and 
CD4 T- cell count for HCV/HIV co-infection subj ects), physica l exainin ations, vital signs 
measurements at vai·ious time po ints during the s tudy, and by the documentation of AEs. 
All safety data collected on or after the first dose of study drng administratio n up to 30 days after 
the last dose of study drng will be summai· ized by ti·eatme nt group acco rding to the stu dy diug 
received. 
8.6.1. Extent of Exposure 
A su bject's extent of exposure to study drng will be generated from the study diu g 
adinini sti·ation page of the CRF. Exposure data will be sUIIllnai·ized by ti·eatme nt group. 
CONFIDENTIAL Page 66 02 March 2017 
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 67 02March 20178.6.2. Adverse Events
Clinical and laboratory  adverse events will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Sy stem Organ Class (SOC), High -Level Group Term 
(HLGT), High -Level Term (HL T), Preferred Term (PT), and Lower -Level Term (LLT) will be 
attached to the clinical database.
Events will be summarized on the basis of the date of onset for the event. A treatment -emergent 
adverse event will be defined as an y adverse event that begin son or 
after the date of first dose of 
study drug up to the date of last dose of study  drug plus 30 day s.
Summaries (number and percentage of subjects) of treatment -emergent adverse events (b y SOC, 
and PT) will be provided by  treatment group:
All AEs
AEs of Grade 3 or above
AEs of Grade 2 or above
All treatment -related AEs
Treatment -related AEs of Grade 3 or above
Treatment -related AEs of Grade 2 or above
All SAEs
All treatment -related SAEs
All AEs leading to premature discontinuation of the study  drug
All AEs leading to temporary  interruption of th e study  drug
All AEs collected during the study  will be presented in the data listings. 
8.6.3. Laboratory Evaluations
Graded laboratory  abnormalities will be defined using the laboratory  toxicity  grading defined in 
Appendix 3. The incidence of treatment -emergent laboratory  abnormalities, defined as values 
that increase b y at least one toxicity  grade from Baseline/Day  1 at any  time postbaseline, up to 
the date of last dose of study  drug plus 30 day s will be summarized by  treatment group.
Values for missing safety laboratory  data will not be imputed; however, a missing 
Baseline/Day 1 result will be replaced with a screening result, if available. If no pretreatment 
laboratory  value is available, the Baseline/Day  1 value will be assumed to b e normal 
(i.e., nograde [G rade 0]) for the summary  of graded laboratory  abnormalities.
All laboratory  abnormalities will be included in the listings of laboratory  data
LDV/SOF 
Protoco l GS-US-337-4063 
Gilead Sciences , Inc. 
8.7. Other Safety Evaluations Final 
Amendmen t 3.0 
Individual data for 12-lead ECG , vital signs measurement s will be listed by subject and 
summarized by treatment group by incidence of events /abn01malities or descriptive statistical 
summarie s (n, mean , SD, medi an, Ql, Q3, minimum , and maximum ), as appropriate . 
8.8. Pharmacokinetic Analysis 
In the PK analysis set, plasma concentrations of the study dmg over time will be listed. Detail s 
of the analysis will be provided in the pha1m acokineti c rep01tin g and analysis plan. 
8.9. Sample Size 
With a sample size of 100 subjects, a 2-s ided 95% exact confiden ce inte1val will extend at the 
most 20% in length. 
8.10. Data Monitoring Committee 
An external multidi sciplina1 y data monitoring committee (DM C) will review the progress of the 
study and perf01m an interim review of safety data once the first 12 subjects have completed 8 
weeks of treatment , or early te1min ation. After the initial meetin g, safety reviews will be 
conducted at approximatel y 3 month inte1vals durin g the trial until the last emolled subject 
complete s study treatment. These safety reviews will altern ate between the following : 
• A review by the DMC cha ir of all SAEs and deaths 
• A review of safety data by the DMC meetin g as specified in the DMC cha1ter 
The DMC will provide recommendation to Gilead on whether the nature , frequen cy, and severity 
of adve rse effects assoc iated with study treatment wauant the early te1mination of the study in 
the best intere sts of the pa1ti cipants, whether the study should continue as planned , or the study 
should continue with modifi cations. The DMC may also provide recommendation s as needed 
regarding study design , conduct, and the need for additional meetin gs or an alternati ve meetin g 
schedule . The DMC 's specific activities will be defined by a mutuall y agreed chaite r, which will 
define the DMC 's member ship, cond uct and meetin g sched ule. 
While the DMC will be asked to advise Gilead regai·ding future conduct of the study, includin g 
possible early study te1mination , Gilead retains final decision-making authority on all aspects of 
the study. 
CONF IDENTIAL Page 68 02 March 2017 
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 69 02March 20179. RESPONSIBILITIES
Investigator Responsibilities 9.1.
9.1.1. Good Clinical Practice
The investigator will e nsure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki, (as amended in Edinburgh, Toky o, Venice, Hong Kong, and 
South Africa) ,International Conference on Harmonisation (I CH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study  subject. :These standards are consistent with the Europea n Union Clinical 
Trials Directive 2001/20/EC and G ood Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as outlined in 21 CFR 312, subpart D, “Responsibilities of Spons ors and Investigators,” 
21CFR, part50, 1998, and 21 CFR, part 56, 1998 .
The investigator and all applicable subinvestigators will comply  with 21 CFR, Part 54, 1998, 
providing documentation of their financial interest or arrangements with Gilead, or proprietary interests in the investigational drug under stud y. This documentation must be provided prior to 
the investigator’s (and any subinvestigator’s) participation in the study . The investigator and 
subinvestigator agree to notify  Gilead of an y change in reportabl e interests during the stud y and 
for 1 year following completion of the study. Study completion is defined as the date when the 
last subject completes the protocol -defined activities.
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed consent) to an IRB/IEC. The investigator will not begin an y study subject activities 
until approval from the IRB/IEC has been documented and provided as a letter to the 
investigator.
Before implementation, the investigator will submit to and receive documented approval from 
the IRB/IEC /ECany modifications made to the protocol or an y accompan ying material to be 
provided to the subject after initial I RB/IEC approval , with the exception of those necessary  to 
reduce immediate risk to study  subjects.
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and potential haza rds of the study  and before undertaking any stud y-related procedures. 
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 70 02March 2017Theinvestigator must use the most current IRB/IECapproved consent form for documenting 
written informed consent. Each informed consent (or assent as applicable) will be appropriatel y 
signed and dated b y the subject or the subject’s legally authorized representative and the person 
conducting the consent discussion, and also by  an impartial witness if required b y IRB/IEClocal
requirements.The consent form will inform subjects about pharmacogenomic testing and sample 
retention, and their right to receive clinicall y relevant pharmacogenomic analysis results.
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity  will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only  subject initials, date of birth, another 
unique identifier (as allowed b y local law) and an identifica tion code will be recorded on an y 
form or biological sample submitted to the Sponsor , IRB/IEC,or laboratory . Laboratory  
specimens must be labeled in such a way  as to protect subject identity  while allowing the results 
to be recorded to the proper subject. Refer to s pecific laboratory  instructions for further details.
NOTE :Theinvestigator must keep a screening log showing codes, names, and addresses for all 
subjects screened and for all subjects enrolled in the trial. Subject data will be processed in 
accordance with all applicable regulations.
The investigator agrees that all information received from Gilead, including but not limited to the 
investigator brochure, this protocol, CRF /eCRF , the IMP, and an y other study information, 
remain the sole and exclusive propert y of Gilead during the conduct of the study and thereafter. 
This information is not to be disclosed to an y third party (except emplo yees or agents directly  
involved in the conduct of the study  or as required by  law) without prior written consent from 
Gilead. The investigator further agrees to take all reasonable precautions to prevent the disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investig ator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the following two categories: (1)investigator’s study  file, and 
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, CRF and query  forms, 
IRB/IECand governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identification (n ame, date of birth, gender);
Documentation that subject meets eligibility  criteria, ie, history , phy sical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 71 02March 2017Documentation of the reason(s) a consented subject is not en rolled;
Participation in study  (including study  number);
Study  discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were performed;
Results of efficacy  parameters, as required b y the protocol;
Start a nd end date (including dose regimen) of IMP, including dates of dispensing and return;
Record of all adverse events and other safety  parameters (start and end date, and including 
causality  and severity );
Concomitant medication (including start and end date , dose if relevant; dose changes);
Date of study  completion and reason for earl y discontinuation, if it occurs.
All clinical study  documents must be retained b y the investigator until at least 2 years or 
according to local laws, whichever is longer, after the last approval of a marketing application in 
an ICH region (i .e., United States, Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved fo r such indication, until 2 years after the investigation is discontinued and regulatory 
authorities have been notified. Investigators may  be required to retain documents longer if 
specified by  regulatory  requirements, by  local regulations, or b y an agreeme nt with Gilead. 
Theinvestigator must notify  Gilead before destroy ing any clinical study  records.
Should the investigator wish to assign the stud y records to another part y or move them to another 
location, Gilead must be notified in advance.
If the investigator cannot provide for this archiving requirement at the study  site for any  or all of 
the documents, special arrangements must be made between the investigator and Gilead to store 
these records securel y awa y from the site so that they  can be returned sealed to the investigator 
in case of a n inspection. When source documents are required for the continued care of the 
subject, appropriate copies should be made for storage away  from the site.
9.1.6. Case Report Forms
For each subject consented, an eCRF casebook will be completed b y an authorized study staff 
member whose training for this function is completed in EDC. The eCRF casebook will only  
capture the data required per the protocol schedule of events and procedure s. The 
Inclusion/Exclusion Criteria and Enrollment eCRFs should be completed only  after all data 
related to eligibility have been received. Subsequent to data entry , a stud y monitor will perform 
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 72 02March 2017source data verification within the EDC sy stem. Sy stem -genera ted or manual queries will be 
issued to the investigative site staff as data discrepancies are identified b y the monitor or internal 
Gilead staff, who routinely  review the data for completeness, correctness, and consistency . The 
site coordinator is respons ible for responding to the queries in a timel y manner, within the 
system, either b y confirming the data as correct or updating the original entry, and providing the 
reason for the update (e.g. data entry  error). Original entries as well as any  changes to data fields 
will be stored in the audit trail of the sy stem. Prior to any  interim time points or database lock (as 
instructed by  Gilead), the investigator will use his/her log in credentials to confirm that the forms 
have been reviewed, and that the entries accurately  reflect the information in the source 
documents. At the conclusion of the trial, Gilead will provide the site with a read -only archive 
copy  of the data entered by  that site. This archive must be stored in accordance with the records 
retention r equirements outlined in Section 9.1.5.
9.1.7. Investigational Medicinal Product Accountability and Return
Where possible, IMP should be destro yed at the site. If the site does not have acceptable
procedures in place for drug destruction, arrangements will be made between the site and Gilead 
Sciences (or Gilead Sciences’ representative) for return of used and unused IMPsupplies.
The study  monitor will provide instructions for return.
The study  monitor will evaluate each study  center’s study  drug disposal procedure s and provide
appropriate instruction for destruction of unused IMP supplies. I f the site has an appropriate 
standard operating procedure (SOP) for drug destruction as determined b y Gilead, the site may  
destroy  used (empt y or partially empty) and unused IMPsupplies in accordance with that site’s 
approved SOP. A cop y of the site’s approved SOP will be obtained for central files.
If IMP is destro yed on site, the investigator must maintain accurate records for all IMP
destroy ed. Records must show the identifi cation and quantity  of each unit destroy ed, the method 
of destruction, and the person who disposed of the IMP. Upon study  completion, copies of the 
IMP accountability records must be filed at the site. Another copy  will be returned to Gilead.
Refer to the Pharmacy  Binder for stud y drug disposal/return instructions .
The study  monitor will review IMP supplies and associated records at periodic intervals.
9.1.8. Inspections
The Investigator will make available all source documents and other records for this trial to 
Gilead’s appointed stud y monitors , to IRB/IEC , or to regulatory  authorit y or health authorit y 
inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 73 02March 2017Sponsor Responsibilities 9.2.
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study subjects, may be 
made only  by Gilead. The investigator must submit a ll protocol modifications to the IRB/IECs in
accordance with local requirements and receive documented IRB/ IECs approval before 
modifications can be implemented.
9.2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared and provided to the regulatory agency. Gilead will 
ensure tha t the report meets the standards set out in the I CH Guideline for Structure and Content 
of Clinical Study  Reports (I CHE3). Note that an abbreviated report may  be prepared in certain 
cases.
Investigators in this study  may  communicate, orally  present, or publish in scientific journals or 
other scholarl y media only after the following conditions have been met:
The results of the stud y in their entirety have been publicly disclosed b y or with the consent of 
Gilead in an abstract, manuscript, or presentation fo rm or the stud y has been completed at all 
study  sites for at least 2 years .
The investigator will submit to Gilead any proposed publication or presentation along with the 
respective scientific journal or presentation forum at least 30 day s before submission of the 
publication or presentation. 
No such communication, presentation, or publication will include Gilead’s confidential 
information (see Section 9.1.4 ).
The investigator will comply  with Gilead’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtai n patent protection if 
deemed necessary .
Joint Investigator/Sponsor Responsibilities 9.3.
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, e.g. attendance at I nvestigator's Meetings. If requir ed under the applicable statutory  and 
regulatory  requirements, Gilead will capture and disclose to Federal and State agencies an y 
expenses paid or reimbursed for such services, including an y clinical trial payments, meal, travel 
expenses or reimbursements, consulting fees, and any  other transfer of value.
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 74 02March 20179.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the study  monitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy  of the data recorded in the 
CRF /eCRF .
The monitor is responsible for routine review of the CRF /eCRF at regular intervals throughout 
the study  to verify  adherence to the protocol and the completeness, consistency , and accuracy  of 
the data being ent ered on them. The monitor should have access to an y subject records needed to 
verify  the entries on the CRF /eCRF . The investigator agrees to cooperate with the monitor to 
ensure that an y problems detected through any  type of monitoring (central, on site) are resolved.
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of Gilead may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify  the Gilead medical monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency  or Gilead access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at an y time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authorit y(ies), I RBs, and I ECs. In terminating the study , Gilead and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 75 02March 201710. REFERENCES
AbbVie Inc. VIEKIRA XR (dasabuvir, ombitasvir, paritaprevir, and ritonavi r) extended -release 
tablets, for oral use. US Prescribing Information. North Chicago, IL. Revised 
July.  2016:
Allison RD, Tong X, Moorman AC, Ly  KN, Rupp L , Xu F, et al. Increased Incidence of Cancer 
and Cancer -related Mortality  Among Persons with Chronic Hepatitis C I nfection, 
2006- 2010. J Hepatol 2015.
Arias A, Aguilera A, Soriano V, Benitez
-Gutierrez L , Lledo G, Navarro D, et al. Rate and 
predictors of treatment failure to all- oral HCV regimens outside clinical trials. 
Antivir Ther 2016.
Bhamidimarri KR, Czul F, Pey ton A, Levy  C, Hernandez M, Jeffers L, et al. Safety, efficacy  and 
tolerability  of half -dose sofosbuvir plus simeprevir in treatment of Hepatitis C in 
patients with end stage renal disease. J Hepatol 2015;63 (3):763 -5.
Bristol -Myers Squibb. DAKLINZA™ (daclatasvir) tablets, for oral use. US Prescribing 
Information. Princeton, NJ. Revised April.  2016:
Desno yer A, Pospai D, Le MP, Gervais A, Heurgue -Berlot A, Laradi A, et al. Pharmacokinetics, 
safet y and efficacy of a full dose sofosbuvir -based regimen given dail y in 
hemodialy sis patients with chronic hepatitis C [Article in Press]. J Hepatol 2016.
Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus 
infection on survival in dialy sis patients: meta -analy sis of observational studies. J 
Viral Hepat 2007;14 (10):697
-703.
Gilead Sciences Inc. HARVONI® (ledipasvir and sofosbuvir) tablets, for oral use. US 
Prescribing Information.  Foster City, CA. Revised November 2015a:
Gilead Sciences Inc. SOVALDI® (sofosbuvi r) tablets, for oral use. US Prescribing Information.  
Foster City , CA. Revised August 2015b:
Gilead Sciences Inc. EPCL USA® (sofosbuvir and velpatasvir) tablets, for oral use. US 
Prescribing Information. Foster City , CA. Revised June.  2016:
Gower E, Estes C, Blach S, Razavi- Shearer K, Razavi H. Global epidemiology  and genot ype 
distribution of the hepatitis C virus infection. J Hepatol 2014.
Hundemer GL, Sise ME, Wisocky  J, Ufere N, Friedman L S, Corey  KE, et al. Use of sofosbuvir -
based direct -acting antivir al therap y for hepatitis C viral infection in patients with 
severe renal insufficiency. Infectious diseases 2015;47 (12):924 -9.
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 76 02March 2017Ioannou GN, Beste LA, Chang MF, Green PK, Lowey  E, Tsui J I, et al. Effectiveness of 
Sofosbuvir, L edipasvir/Sofosbuvir, or Parita previr/Ritonavir/Ombitasvir and 
Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans 
Affairs National Healthcare S ystem [Accepted Manuscript]. Gastroenterology  
2016;151:457-71.
Kidney  Disease: I mproving Global Outcomes. KDIGO clini cal practice guidelines for the 
prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney  
disease. Kidney  international. Supplement 2008 (109):S1-99.
Merck & Co Inc. ZEPATIER™ (elbasvir and grazoprevir) tablets, for oral use. US Pre scribing 
Information. Whitehouse Station, NJ. Revised January .  2016:
Morgan RL , Baack B, Smith BD, Yartel A, Pitasi M, Falck -Ytter Y. Eradication of Hepatitis C 
Virus Infection and the Development of Hepatocellular Carcinoma. Ann Intern 
Med 2013;158 (5 (P art I)).
Navarro- Millan I, Sattui SE, Curtis JR. Sy stematic review of tumor necrosis factor inhibitor 
discontinuation studies in rheumatoid arthritis. Clin Ther 2013;35 (11):1850 -61 
e1.
Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genot ype 1 -patients 
with end- stage renal disease on haemodial ysis or GFR <30 ml/min. L iver Int 
2016;36 (6):798 -801.
Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus 
and hepatitis C virus infections to cirrho sis and primary  liver cancer worldwide. J 
Hepatol 2006;45 (4):529-38.
Poynard T, McHutchison J, Manns M, Trepo C, L indsay  K, Goodman Z, et al. I mpact of 
pegy lated interferon alfa -2b and ribavirin on liver fibrosis in patients with chronic 
hepatitis C. Gast roenterology  2002;122 (5):1303-13.
van der Meer AJ, Veldt BJ, Feld JJ, Wedemey er H, Dufour JF, Lammert F, et al. Association 
between sustained virological response and all -cause mortality  among patients 
with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308 
(24):2584-93.
Veldt BJ, Heathcote EJ, Wedemey er H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained 
virologic response and clinical outcomes in patients with chronic hepatitis C and 
advanced fibrosis. Ann Intern Med 2007;147 (10):677-84.
World Health Organization (WHO). Hepatitis C Fact Sheet No. 164. Available at: 
http://www.who.int/mediacentre/factsheets/fs164/en/#. Accessed 20 June 2014:1 -
7.
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 77 02March 201711. APPENDICES
Appendix 1. Investigator Signature Page
Appendix 2. Study Procedures Table
Appendix 3. GSI Grading Scale for Severity of Adverse Events and Laboratory 
Abnorm alities
Appendix 4. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
Appendix 5. Opportunistic Infections
Appendix Table 1. Screening/Baseline/ On -Treatment and Post Treatment Study Visits for Group 1
Appendix Table 2. Screening/Baseline/ On -Treatment and Post Treatment Study Visits for Group 2
Appendix Table 3. Screening/Baseline/ On -Treatment and Post Treatment Study Visits for Group 3
LDV/SOF 
Protocol GS-US-337-4063 Final 
Gilead Sciences, Inc. Amendment 3.0 
App endix 1. Investigator Signature Page 
GILEAD SCIENCES, INC. 
333 LAKESIDE DRIVE 
FOSTER CITY , CA 94404 
STUDY ACKNOWLEDGEMENT 
A Phase 2, Multicenter, Open -Label Study to Evaluate the Efficacy and Safety of 
Ledipasvir/Sofosbuvir in Subjects with Genotype 1, 4, 5 and 6 Chronic HCV Infection Who are 
on Dialysis for End Stage Renal Disease 
GS-US-337-4063, Amendment 3.0, 02 March 2017 
This protocol has been approved by Gilead Sciences, Inc. The following signature documents 
[P~D _ i P _P _ D ____ _ 
PPD Signature 
Medical Monitor 
Date 
..- ,..... INVESTIGATOR STATEMENT 
I have read the protocol, incJuding all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described . I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated . 
I will provide all study personnel under my supervision copies of the protocol and access to all 
information provided by Gilead Sciences, Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator Name (Printed) Signature 
Date Site Number 
CONFID ENTIAL Page 78 02 March 2017 
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 79 02March 2017Appendix 2. Study Procedures Table
Appendix Table 1. Screening/ Baseline/ On -Treatment and Post Treatment Study Visits for Group 1
Screen Baseline/Day 1aOn-Treatm ent Week (±3 Days) Post-Treatm ent Week (±5 Days)
2 4 6 8 /ET 4 12 24
Informed Consent X
Determine Eligibility X X
Medical History X
Physical Examination X X X X X X
Height X
Weight X X X
Vital Signs X X X X X X X X X
12-Lead ECG X X X
AEs/SAEbX X X X X X X XbXb
Concomitant Medications X X X X X X X
Pregnancy Prevention Counseling X X X X X
Health -Related Quality of LifecX X X
Revie w of Study Medication 
Com plianceX X X X
Study Drug DispensingdX X
Hem atology, Chemistry X X X X X X X X X
Coagulation Tests X X X
HCV RNA X X X X X X X X X
Viral Sequencing /PhenotypingeX X X X X X X X
Sparse PK X X X X
Intensive PKg, hXhXh
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 80 02March 2017Screen Baseline/Day 1aOn-Treatm ent Week (±3 Days) Post-Treatm ent Week (±5 Days)
2 4 6 8 /ET 4 12 24
Hem odialysis PKg, iXiXi
Serum β -hCG Pregnancy TestjX X X X X
Serum Drug Screen X
HCV & IL28B Genotyping X
HCV, HIV, HBV Serology X
HBV DNAkX X X X X X
HbA1c X
Fibrotest®X
Archive SamplefX X
Pharm acogenomic SamplefX
CD4 Cell CountlX X X X X
HIV-1 RNAlX X X X X
a Baseline/Day 1 assessments must be performed prior to dosing
b Only SAEs will be collected at post -treatment Weeks 12 and 24.
c Health Related Quality of Life (HRQoL) Surveys (e .g.,SF-36, CLDQ -HCV, FACI T-F and WPAI) will be conducted for all subjects wher e the surveys are available at Day 1, 
Week 8, ET (if applicable) , and posttreatment Week 12.
d The IWRS will provide direction on the specifics of each subject’s study drug dispensing
e. Plasma samples will be collected for possible viral resistance testing and other virology studies
f Subjects may opt out of archive /pharmacogenomics sample collection.
g Only for subjects who have provided consent for this sample and testing. 
h Intensive PK evaluations will be assessed at the following timepoints: 0 (pre-dose -5 minutes), 0.25, 0.5, 1, 2, 4, 6 ,8, 10, and 12 hours post dose once either on Week 6 or 8, 
per investigator discretion.
i Hemodialysis PK blood samples will be collected at one hemodialysis session between Week 6 and Week 12, inclusive (as app ropri ate based on treatment group ),evaluations 
will include: 1. A single blood sample will be collected within 10 minutes before hemodialysis initiates. 2. During hemodialysis, a single sample will be collected from both 
the arterial and venous sides of the dialyzer within 1 hour of hemodialysis concluding. 3. Finally, a single blood sample will be collected within 10 minutes after hemodialysis 
concludes .
j For females of child bearing potential only
k. Only for subjects who are HBcAb + at Screening
l For H IV/HCV co -infected subjects only.
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 81 02March 2017Appendix Table 2. Screening/ Baseline/ On -Treatment and Post Treatment Study Visits for Group 2
Screen Baseline/Day1aOn-Treatm ent Week (±3 Days) Post-Treatm ent Week (±5 Days)
2 4 6 8 12/ET 4 12 24
Informed Consent X
Determine Eligibility X X
Medical History X
Physical Examination X X X X X X
Height X
Weight X X X
Vital Signs X X X X X X X X X X
12-Lead ECG X X X
AEs/SAEbX X X X X X X X XbXb
Concomitant Medications X X X X X X X X
Pregnancy Prevention 
CounselingX X X X X X
Health -Related Quality of LifecX X X
Revie w of Study Medication 
Com plianceX X X X X
Study Drug DispensingdX X X
Hem atology, Chemistry X X X X X X X X X X
Coagulation Tests X X X
HCV RNA X X X X X X X X X X
Viral Sequencing /PhenotypingeX X X X X X X X X
Sparse PK X X X X X
Intensive PKg, hXhXhXh
Hem odialysis PKg, iXiXiXi
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 82 02March 2017Screen Baseline/Day1aOn-Treatm ent Week (±3 Days) Post-Treatm ent Week (±5 Days)
2 4 6 8 12/ET 4 12 24
Serum β -hCG Pregnancy TestjX X X X X X
Serum Drug Screen X
HCV & IL28B Genotyping X
HCV, HIV, HBV Serology X
HBV DNAkX X X X X X X
HbA1c X
Fibrotest®X
Archive SamplefX X
Pharm acogenomic SamplefX
CD4 Cell CountlX X X X X X
HIV-1 RNAlX X X X X X
a Baseline/Day 1 assessments must be performed prior to dosing
b Only SAEs will be collected at post -treatment Weeks 12 and 24.
c Health Related Quality of Life (HRQoL) Surveys (e .g.,SF-36, CLDQ -HCV, FACI T-F and WPAI) will be conducted for all subjects where the surveys are available at Day 1, 
Week 12 , ET (if applicable) ,and posttreatment Week 12.
d The IWRS will provide direction on the specifics of each subject’s study drug dispensing
e Plasma samples will be collected for possible viral resistance testing and other virology studies
f Subjects may opt out of archive /pharmacogenomics sample collection.
g Only for subjects who have provided consent for this sample and testing. 
h Intensive PK evaluations will be assessed at the following timepoints: 0 (pre -dose -5 minutes), 0.25, 0.5, 1, 2, 4, 6 ,8, 10, and 12 hours post dose once either on Week 6 ,8,or 
12per investigator discretion.
i Hemodialysis PK blood samples will be collected at one hemodialysis session between Week 6 and Week 12, inclusive (as appropri ate based on treatment regimen),
evaluations will include: 1. A single blood sample will be collected within 10 minutes before hemodialysis initia tes. 2. During hemodialysis, a single sample will be collected 
from both the arterial and venous sides of the dialyzer within 1 hour of hemodialysis concluding. 3 . Finally, a single blood sample will be collected within 10 minutes after 
hemodialysis concludes . 
j For females of child bearing potential
k. Only for subjects who are HBcAb + at Screening
l For HIV/HCV co -infected subjects only.
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 83 02March 2017Appendix Table 3. Screening/ Baseline/ On -Treatment and Post Treatment Study Visits for Group 3
Screen Baseline/Day1aOn-Treatm ent Week (±3 Days) Post-Treatm ent Week (±5 Days)
2 4 6 8 12 16 20 24/ET 4 12 24
Informed Consent X
Determine Eligibility X X
Medical History X
Physical Examination X X X X X X
Height X
Weight X X X
Vital Signs X X X X X X X X X X X X X
12-Lead ECG X X X
AEs/SAEbX X X X X X X X X X X XbXb
Concomitant 
MedicationsX X X X X X X X X X X
Pregnancy Prevention 
CounselingX X X X X X X X X
Health -Related Quality 
of Lifec X X X
Revie w of Study 
Medication ComplianceX X X X X X X X
Study Drug DispensingdX X X X X X
Hem atology, Chemistry X X X X X X X X X X X X X
Coagulation Tests X X X
HCV RNA X X X X X X X X X X X X X
Viral Sequencing /
Phenotypinge X X X X X X X X X X X X
Sparse PK X X X X X X X X
Intensive PKg, hXhXhXh
Hem odialysis PKg, iXiXiXi
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 84 02March 2017Screen Baseline/Day1aOn-Treatm ent Week (±3 Days) Post-Treatm ent Week (±5 Days)
2 4 6 8 12 16 20 24/ET 4 12 24
Serum β -hCG
Pregnancy Testj X X X X X X X X X
Serum Drug Screen X
HCV & IL28B 
Genotyping X
HCV, HIV, HBV 
SerologyX
HBV DNAkX X X X X X X X X X
HbA1c X
Fibrotest®X
Archive SamplefX X
Pharm acogenomic 
Samplef X
CD4 Cell CountlX X X X X X X X X
HIV-1 RNAlX X X X X X X X X
a Baseline/Day 1 assessments must be performed prior to dosing
b Only SAEs will be collected at post -treatment Weeks 12 and 24.
c Health Related Quality of Life (HRQoL) Surveys (e .g.,SF-36, CLDQ -HCV, FACI T-F and WPAI) will be conducted for all subjects where the surveys are available at Day 1, 
Week 24 , ET (if applicable), and posttreatment Week 12.
d The IWRS will provide direction on the specifics of each subject’s study drug dispensing
e
Plasma samples will be collected for possible viral resistance testing and other virology studies
f Subjects may opt out of archive /pharmacogenomics sample collection.
g Only for subjects who have provided consent for this sample and testing. 
h Intensive PK evaluations will be assessed at the following timepoints: 0 (pre -dose -5 minutes), 0.25, 0.5, 1, 2, 4, 6 ,8, 10, and 12 hours post dose once either on Week 6 8,or 
12 per investigator discretion.
i
Hemodialysis PK blood samples will be collected at one hemodialysis session between Week 6 and Week 12, inclusive (as appropri ate based on treatment regimen),
evaluations will include: 1. A single blood sample will be collected within 10 minutes before hemodialysis initiates . 2. During hemodialysis, a single sample will be collected 
from both the arterial and venous sides of the dialyzer within 1 hour of hemodia lysis concluding. 3. Finally a
single blood sample will be collected within 10 minutes after 
hemodialysis concludes.
j For females of child bearing potential
k. Only for subjects who are HBcA b+at Screening
l For HIV/HCV co -infected subjects only.
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 85 02March 2017Appendix 3. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Antiviral Toxicity Grading Scale Version: 01 April 2015
HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hem oglobin
HIV POSITIVE
Adult and Pediatric 57 Days8.5to10.0 g/dL
85 to 100 g/L7.5to 8.5g/dL
75to85g/L6.5 to 7.5g/dL
65 to 75g/L6.5g/dL
65g/L
HIV NEGATIVE
Adult and Pediatric 57 Days 10.0 to10.9 g/dL
100to109g/L
OR
Any decrease from Baseline
2.5 to 3.5g/dL
25 to 35g/L9.0 to 10.0 g/dL
90 to 100g/L
OR
Any decrease from Baseline
3.5 to 4.5g/dL
35 to 45g/L7.0 to 9.0g/dL
70 to 90g/L
OR
Any decrease from Baseline
4.5g/dL
45g/L7.0g/dL
70g/L
Infant, 36 –56 Days
(HIV POSITIVE OR
NEGATIVE )8.5 to 9.4 g/dL
85 to 94 g/L7.0 to 8.5g/dL
70 to 85g/L6.0 to 7.0 g/dL
60 to < 70 g/L6.0 g/dL
< 60 g/L
Infant, 22 –35 Days
(HIV POSITIVE OR
NEGATIVE )9.5 to 10.5 g/dL
95 to 105 g/L8.0 to 9.5g/dL
80 to 95g/L7.0 to 8.0g/dL
70 to 80g/L7.0g/dL
70g/L
Infant, 1 –21 Days
(HIV POSITIVE OR
NEGATIVE )12.0 to 13.0 g/dL
120 to 130 g/L10.0 to 12.0 g/dL
100 to 120g/L9.0 to 10.0 g/dL
90 to 100g/L9.0g/dL
90g/L
Absolute Neutrophil Count  
(ANC)
Adult and Pediatric, 
≥ 7 Months#1000 to1300/mm3750to1000/mm3500to750/mm3500/mm3
1.00 to 1.30 GI/L 0.75 to 1.00 GI/L 0.50 to0.75 GI/L 0.50 GI/L
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 
>13Years300to400/mm3
300to400/μL200to300/mm3
200to 300/μL100to200/mm3
100to200/μL100/mm3
100/μL
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 86 02March 2017HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 
13Years600 to 650/mm3
0.60 to 0.65 GI/L500 to 600/mm3
0.50 to 0.60 GI/L350 to 500/mm3
0.35 to 0.50 GI/L350/mm3
0.35 GI/L
Platelets 100,000 to < 125,000/mm3
100to125 GI/L50,000 to 100,000/mm3
50to 100 GI/L25,000 to 50,000/mm3
25 to 50 GI/L25,000/mm3
25GI/L
WBCs 2000/mm3to 2500/mm31,500 to  2,000/mm31000 to 1,500/mm31000/mm3
2.00 GI/L to 2.50 GI/L 1.50 to 2.00 GI/L 1.00 to 1.50 GI/L 1.00 GI/L
Hypofibrinogenemia 100to200mg/dL 75 to 100mg/dL 50to 75mg/d L 50mg/d L
1.00 to2.00 g/L 0.75 to 1.00 g/L 0.50 to 0.75 g/L 0.50 g/L
Hyperfibrinogenemia ULN to 600 mg/dL 600mg/dL — —
ULN  to 6.0 g/L 6.0g/L — —
Fibrin Split Product 20 to 40 μg/mL 40to 50μg/mL 50to 60μg/mL 60μg/mL
20 to 40 mg/L 40 to 50 mg/L 50 to 60mg/L 60mg/L
Prothrombin Time (PT) 1.00 to 1.25 ULN 1.25 to 1.50 ULN 1.50 to 3.00 ULN 3.00 ULN
International Normalized Ratio 
of prothrombin time (INR)1.1 to 1.5 x ULN >1.5 to 2.0 x ULN >2.0 to 3.0 x ULN >3.0 x ULN
Activated Partial
Thromboplastin Time (APTT) 1.00 to 1.66 ULN 1.66 to 2.33 ULN 2.33 to 3.00 ULN 3.00 ULN
Methemoglobin 5.0to10.0% 10.0 to15.0% 15.0 to20.0% 20.0%
# An overlap between the Grade 1 scale and the Lab’s normal range for absolute neutrophils may result for pediatric subjects.  Please follow the Gilead convention of grading 
any resu lt within the LLN and ULN a 0.
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 87 02March 2017CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130 to <LLN mEq/L 125 to 130mEq/L 121 to 125mEq/L 121 mEq/L
130 to <LLN mmol/L 125 to 130mmol/L 121 to 125mmol/L 121 mmol/L
Hypernatremia >ULN  to 150 mEq/L 150 to 154 mEq/L 154 to 159 mEq/L 159 mEq/L
>ULN  to 150 mmol/L 150 to 154 mmol/L 154 to 159 mmol/L 159 mmol/L
Hypokalemia 
Adult and Pediatric
1 Year3.0 to  <LLN mEq/L 2.5 to 3.0mEq/L 2.0 to 2.5mEq/L 2.0 mEq/L
3.0 to <LLN mmol/L 2.5 to 3.0mmol/L 2.0 to 2.5mmol/L 2.0 mmol/L
Infant  <1 Year 3.0 to 3.4 mEq/L
3.0 to 3.4 mmol/L2.5 to 3.0mEq/L                
2.5 to <3.0 mmolL2.0 to 2.5mEq/L                 
2.0 t o <2.5 mmolL2.0 mEq/L                         
<2.0 mmolL
Hyperkalemia 
Adult and Pediatric
1 Year5.6 to 6.0 mEq/L
5.6 to 6.0 mmol/L6.0 to 6.5 mEq/L
6.0 to 6.5mmol/L6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L7.0 mEq/L
7.0 mmol/L
Infant  <1 Year >ULN to 6.0 mEq/L           
>ULN to 6.0 mmol/L> 6.0 to 6.5 mEq/L
> 6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L             
6.5 to 7.0 mmol/L7.0 mEq/L                  
7.0 mmol/L
Hypoglycemia
Adult and Pediatric
1Month55 to 64 mg/dL
3.03 to 3.58 mmol/L40 to 55mg/d L
2.20 to 3.03 mmol/L30 to 40mg/d L
1.64 to 2.20 mmol/L30 mg/dL
1.64 mmol/L
Infant, 1Month 50 to 54 mg/dL
2.8 to 3.0 mmol/L40 to 50mg/d L
2.2 to 2.8mmol/L30 to 40mg/d L
1.7 to 2.2mmol/L30 mg/dL
1.7 mmol/L
Hyperglycemia, Nonfasting 116to 160 mg/dL 160 to 250 mg/dL 250 to 500 mg/dL 500 mg/dL
6.42 to 8.91 mmol/L 8.91 to 13.90 mmol/L 13.90 to 27.79 mmol/L 27.79 mmol/L
Hyperglycemia, Fasting 110 to 125 mg/dL
6.08 to 6.96 mmol/L>125 to 250 mg/dL
>6.96 to 13.90 mmol/L>250 to 500 mg/dL
>13.90 to 27.79 mmol/L>500 mg/dL
>27.79 mmol/L
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 88 02March 2017CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypocalcemia 
(corrected for albumin if 
appropriate*)
Adult and Pediatric
2 Years7.8 <LLN mg/dL
1.94 to <LLN mmol/L7.0 to 7.8 mg/dL
1.74 to 1.94 mmol/L6.1 to 7.0mg/dL
1.51 to 1.74 mmol/L6.1mg/d L
1.51 mmol/L
Pediatric ≥7 days -2 Years 7.8 to 8.4 mg/dL
1.94 to 2.10 mmol/L7.0 to <7.8 mg/dL
1.74 to <1.94 mmolL6.1 to  <7.0 mg/dL
1.51 to < 1.74 mmolL< 6.1 mg/dL
< 1.51 mmol/L
Infant, 7Days 6.5 to 7.5 mg/dL
1.61 to 1.88  mmol/L6.0 to 6.5 mg/dL
1.49 to < 1.61 mmol/L5.5 to 6.0 mg/dL
1.36 to < 1.49 mmol/L5.5 mg/dL
< 1.36 mmol/L
Hypercalcemia (corrected 
for albumin if appropriate*)
Adult and Pediatric 
7Days>ULN to 11.5 mg/dL 11.5 to 12.5 mg/dL 12.5 to 13.5 mg/dL 13.5 mg/dL
>ULN to 2.88 mmol/L 2.88 to 3.13 mmol/L 3.13 to 3.38 mmol/L 3.38 mmol/L
Infant, 7Days 11.5 to 12.4 mg/dL
2.86 to 3.10  mmol/L12.4 to 12.9 mg/dL
> 3.10 to 3.23  mmol/L12.9 to 13.5 mg/dL
> 3.23 to 3.38  mmol/L13.5 mg/dL
> 3.38 mmol/L
Hypocalcemia (ionized) 3.0 mg/dL to LLN 2.5 to < 3.0 mg/dL 2.0 to 2.5 mg/dL 2.0 mg/dL
0.74 mmol/L to LLN 0.62 to 0.74 mmol/L 0.49 to 0.62 mmol/L 0.49 mmol/L
Hypercalcemia (ionized) ULN to 6.0 mg/dL 6.0 to 6.5 mg/dL 6.5 to 7.0 mg/dL 7.0 mg/dL
ULN to 1.50 mmol/L 1.50 to 1.63 mmol/L 1.63 to 1.75 mmol/L 1.75 mmol/L
Hypomagnesemia 1.40 to  <LLN mg/dL
1.2 to <LLN mEq/L1.04 to 1.40 mg/dL
0.9 to   1.2 mEq/L0.67 to 1.04 mg/dL
0.6 to 0.9 mEq/L0.67 mg/dL
0.6 mEq/L
0.58 to <LLN mmol/L 0.43 to 0.58 mmol/L 0.28 to 0.43 mmol/L 0.28 mmol/L
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 89 02March 2017CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypophosphatemia
Adult and Pediatric
14Years2.0 to < LLN mg/dL
0.63  to LLN mmol/L1.5 to 2.0 mg/dL
0.47 to 0.63 mmol/L1.0 to 1.5 mg/dL
0.31 to 0.47 mmol/L1.0 mg/dL
0.31 mmol/L
Pediatric 1 Year– 14 Years 3.0 to <LLN mg/dL
0.96 to <LLN mmol/L2.5 to 3.0 mg/dL
0.80 to < 0.96 mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Pediatric 1Year 3.5 to <LLN mg/dL
1.12 to <LLN mmol/L2.5 to 3.5mg/dL
0.80 to < 1.12 mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Hyperbilirubinemia 
Adult and Pediatric 
>14Days1.0 to 1.5 ULN 1.5 to 2.5 ULN 2.5 to 5.0 ULN 5.0 ULN
Infant, 14Days
(non-hemolytic)NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 to 30.0 mg/dL
> 428 to 513 μmol/L30.0 mg/dL
> 513 μmol/L
Infant, 14Days
(hemolytic)NA NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 mg/dL
> 428 μmol/L
Blood Urea Nitrogen 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Hyperuricemia >ULN to 10.0 mg/dL 10.0 to 12.0 mg/dL 12.0 to 15.0 mg/dL 15.0 mg/dL
>ULN to 597 μmol/L 597 to 716 μmol/L 716 to 895 μmol/L 895 μmol/L
Hypouricemia 
Adult and Pediatric
≥ 1 year
Infant  < 1 Year1.5 mg/dL to LLN
87 μmol/L to LLN1.0 to 1.5 mg/dL
57 to 87 μmol/L0.5 to 1.0 mg/dL
27 to 57 μmol/L0.5 mg/dL
27 μmol/L
N/A 1.0 mg/dl to <LLN -
57 μmol to <LLN0.5 to 1.0 mg/dL
27 to 57 μmol/L0.5 mg/dL
27 μmol/L
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 90 02March 2017CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Creatinine ** 1.50 to 2.00 mg/dL
133 to 177 μmol/L2.00 to 3.00 mg/dL
177 to 265 μmol/L3.00 to 6.00 mg/dL
265 to 530 μmol/L6.00 mg/dL
530 μmol/L
Bicarbonate
Adult and Pediatric 
≥ 4 Years16.0 mEq/L to LLN 11.0 to 16.0 mEq/L 8.0 to 11.0 mEq/L 8.0 mEq/L
16.0 mmol/L to LLN 11.0 to 16.0 mmol/L 8.0 to 11.0 mmol/L 8.0 mmol/L
Pediatric < 4 Years NA 11.0 mEq/Lto <LLN 8.0 to 11.0 mEq/L 8.0 mEq/L
11.0 mmol/L to <LLN 8.0 to 11.0 mmol/L 8.0 mmol/L
Triglycerides
(Fasting)NA 500 to 750 mg/dL
5.64–8.47 mmol/L750 to 1200 mg/dL
8.47–13.55 mmol/L1200 mg/dL
13.55 mmol/L
LDL (Fasting)
Adult130 to 160 mg/dL >160 to 190 mg/dL > 190 mg/dL NA
3.35 to 4.15 mmol/L >4.15 to 4.92 mmol/L >4.92 mmol/L
LDL (Fasting)
Pediatric >2 to <18 years110 to 130 mg/dL >130 to 190 mg/dL > 190 mg/dL NA
2.84 to 3.37 mmol/L >3.37 to  4.92 mmol/L >4.92 mmol/L
Hypercholesterolemia
(Fasting)200 to 239 mg/dL 239 to 300 mg/dL 300 mg/dL NA
5.16 to 6.19 mmol/L 6.19 to 7.77 mmol/L 7.77 mmol/L
Pediatric 18 Years 170 to 199 mg/dL
4.39 to 5.15 mmol/L199 to 300 mg/dL
5.15 to 7.77 mmol/L300 mg/dL
7.77 mmol/LNA
Creatine Kinase 3.0 to 6.0 ULN 6.0 to 10.0 ULN 10.0 to 20.0 ULN 20.0 ULN
* Calcium should be corrected for albumin if albumin is < 4.0 g/dL
** An overlap between the Grade 1 scale and the Lab’s normal range for creatinine may result for Male subjects >70 yrs.  Please follow the Gilead convention of grading any 
result within the LLN and ULN a 0.  
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 91 02March 2017ENZYMES
Grade 1 Grade 2 Grade 3 Grade 4
AST (SGOT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
ALT (SGPT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
GGT 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Alkaline Phosphatase 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Total Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Pancreatic Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Lipase 1.0 to 1.5 ULN 1.5 to 3.0 ULN 3.0 to 5.0 ULN 5.0 ULN
Albumin
Pediatrics <16 years 
≥ 16 years- 2.0 to LLN g/dL
20 to LLN g/L2.0 g/dL
20 g/LNA
3.0 g/dL to LLN
30 g/L to LLN2.0 to 3.0 g/dL
20 to 30 g/L2.0 g/dL
20 g/LNA
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 92 02March 2017URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Hem aturia (Dipstick) 1 2 3-4+ NA
Hem aturia (Quantitative) 
See Note below
                              Females >ULN -10RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
                              Males 6-10 RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Proteinuria (Dipstick) 1 2–3 4 NA
Proteinuria, 24 Hour Collection
Adult and Pediatric 
10 Years200 to999 mg/24 h >999 to 1999 mg/24 h >1999 to3500 mg/24 h 3500 mg/24 h
Pediatric 3 Mo to 
<10Years201 to499 mg/m2/24h >499 to799 mg/m2/24 h >799 to1000 mg/m2/24 h 1000 mg/ m2/24 h
Glycosuria (Dipstick) 1+ 2-3 4 NA
Notes: 
 Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by Covance Laboratory, however for other laboratories, toxicity grades will only be assigned to 
Dipstick Hematuria.
 With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigne d Grade 0.
 If the severity of a clinical AE could fall under either one of two grades (e.g., the severity of an AE could be either Grade 2 or Grade 3), select the higher of the two grades for 
the AE.
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 93 02March 2017CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac Arrhythmia (general)
(By ECG or physical exam)Asymptomatic AND No 
intervention indicatedAsymptomatic AND Non -
urgent medical intervention 
indicatedSymptomatic, non -life-
threatening AND Non -
urgent medical intervention 
indicatedLife-threatening arrhythmia
OR Urgent intervention 
indicated
Cardiac- ischemia/Infarction NA NA Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemiaUnstable angina OR Acute 
myocardial infarction
Hem orrhage (significant acute 
blood loss)NA Symptomatic AND No 
transfusion indicatedSymptomatic AND 
Transfusion of 2units 
packed RBCs (for children 
10cc/kg) indicatedLife-threatening hypotension 
OR Transfusion of 2units 
packed RBCs indicated (for 
children 10cc/kg) indicated
Hypertension (with repeat 
testing at same visit)140–159mmH g systolic
OR
90–99 mmHg diastolic159–179 mmHg systolic
OR
99–109 mmHg diastolic179mmHg systolic
OR
109mmHg diastolicLife-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization (other than 
ERvisit) indicated
Pediatric 17Years (with 
repeat testing at same visit)NA 91st–94th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)≥95th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)Life-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization indicated 
(other than emergency room 
visit)
Hypotension NA Symptomatic, corrected w ith 
oral fluid replacementSymptomatic, IV fluids 
indicatedShock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure
Pericardial Effusion Asymptomatic, small 
effusion requiring no 
interventionAsymptomatic, moderate or 
larger effusion requiring no 
interventionEffusion with non -life-
threatening physiologic
consequences OR Effusion 
with nonurgent intervention 
indicatedLife-threatening consequences 
(eg, tamponade) OR Urgent 
intervention indicated
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 94 02March 2017CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Prolonged PR Interval PR interval 
0.21 to 0.25 secPR interval
0.25 secType II 2nd degree AV 
block OR Ventricular pause 
3.0 secCom plete AV block
Pediatric 16 Years 1st degree AV block
(PR > normal for age and 
rate)Type I 2nd degree AV block Type II 2nd degree AV 
blockCom plete AV block
Prolonged QTc Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baselineAsymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baselineAsymptomatic, QTc interval 
0.50 sec OR Increase in 
interval 0.06 sec above 
baselineLife-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Pediatric 16Years Asymptomatic, QTc interval 
0.450 to 0.464 secAsymptomatic, QTc interval 
0.465 to 0.479 secAsymptomatic, QTc interval 
0.480 secLife-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/Embolism NA Deep vein thrombosis AND 
No intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure)Deep vein thrombosis AND 
Intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure)Embolic event (eg, pulmonary 
embolism, life -threatening 
thrombus)
Vasovagal Episode (associated 
with a procedure of any kind)Present without loss of 
consciousnessPresent with transient loss of 
consciousnessNA NA
Ventricular Dysfunction 
(congestive heart failure, 
CHF)NA Asymptomatic diagnostic 
finding AND intervention 
indicatedNew  onset with symptoms 
OR Worsening symptomatic
CHFLife-threatening CHF
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 95 02March 2017RESPIRATORY
Grade 1 Grade 2 Grade 3 Grade 4
Bronchospasm (acute) FEV1 or peak flow  reduced to 
70% to 80%FEV1 or peak flow  50% to 69% FEV1 or peak flow  25% to 
49%Cyanosis OR FEV1 or peak flow  
25% OR Intubation
Dyspnea or Respiratory 
DistressDyspnea on exertion with no 
or minimal interference with 
usual social & functional 
activitiesDyspnea on exertion causing 
greater than minimal interference 
with usual social & functional 
activitiesDyspnea at rest causing 
inability to perform usual 
social & functional activitiesRespiratory failure with 
ventilatory support indicated
Pediatric 14 Years Wheezing OR minimal 
increase in respiratory rate for 
ageNasal flaring OR Intercostal 
retractions OR Pulse oximetry 
90% to 95%Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
OR Pulse oximetry 90%Respiratory failure with 
ventilatory support indicated
OCULAR/VISUAL
Grade 1 Grade 2 Grade 3 Grade 4
Uveitis Asymptomatic but detectable 
on examSymptomatic anterior uveitis OR 
Medical intervention indicatedPosterior or pan -uveitis OR 
Operative intervention 
indicatedDisabling visual loss in affected 
eye(s)
Visual Changes (from 
baseline)Visual changes causing no or 
minimal interference with 
usual social & functional 
activitiesVisual changes causing greater 
than minimal interference with 
usual social & functional 
activitiesVisual changes causing 
inability to perform usual 
social & functional activitiesDisabling visual loss in affected 
eye(s)
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 96 02March 2017SKIN
Grade 1 Grade 2 Grade 3 Grade 4
Alopecia Thinning detectable by 
study participant or  
caregiver (for disabled 
adults)Thinning or patchy hair loss 
detectable by health care 
providerCom plete hair loss NA
Cutaneous Reaction –Rash Localized macular rash Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesionsDiffuse macular, 
maculopapular, or morbilliform 
rash with vesicles or limited 
number of bullae OR 
Superficial ulcerations of 
mucous membrane limited to 
one siteExtensive o r generalized 
bullous lesions OR 
Stevens -Johnson syndrome 
OR Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Toxic epidermal 
necrolysis (TEN)
Hyperpigmentation Slight or localized Marked or generalized NA NA
Hypopigmentation Slight or localized Marked or generalized NA NA
Pruritis (itching –no skin 
lesions) 
(See also Injection Site 
Reactions: Pruritis associated 
with injection)Itching causing no or 
minimal interference with 
usual social & functional 
activitiesItching causing greater than 
minimal interference with 
usual social & functional 
activitiesItching causing inability to 
perform usual social & 
functional activitiesNA
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 97 02March 2017GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Anorexia Loss of appetite w ithout 
decreased oral intakeLoss of appetite associated with 
decreased oral intake without 
significant weight lossLoss of appetite associated 
with significant weight lossLife-threatening consequences 
OR Aggressive intervention 
indicated [eg, tube feeding or 
total parenteral nutrition]
Ascites Asymptomatic Symptomatic AND Intervention 
indicated (eg, diuretics or 
therapeutic paracentesis)Symptomatic despite 
interventionLife-threatening consequences
Cholecystitis NA Symptomatic AND Medical 
intervention indicatedRadiologic, endoscopic, or 
operative intervention 
indicatedLife-threatening consequences 
(eg, sepsis or perforation)
Constipation NA Persistent constipation requiring 
regular use of dietary 
modifications, laxatives, or 
enemasObstipation with manual 
evacuation indicatedLife-threatening consequences 
(eg, obstruction)
Diarrhea 
Adult and Pediatric 
1YearTransient or intermittent 
episodes of unformed stools 
OR Increase of 3stools 
over baseline/24 hrPersistent episodes of unformed 
to watery stools OR Increase of 
4–6 stools over baseline per 
24hrs.Bloody diarrhea OR Increase 
of 7stools per 24 -hour 
period OR IV fluid 
replacement indicatedLife-threatening consequences 
(eg, hypotensive shock)
Pediatric 1Year Liquid stools (more
unformed than usual) but 
usual number of stoolsLiquid stools with increased 
number of stools OR Mild 
dehydrationLiquid stools with moderate 
dehydrationLiquid stools resulting in 
severe dehydration with 
aggressive rehydration 
indicated OR Hypotensive 
shock
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 98 02March 2017GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Dysphagia -Odynophagia Symptomatic but able to eat 
usual dietSymptoms causing altered 
dietary intake without medical 
intervention indicatedSymptoms causing severely 
altered dietary intake with 
medical intervention indicatedLife-threatening reduction in 
oral intake
Mucositis/Stomatitis 
(clinical exam)
See also Proctitis, 
Dysphagia -OdynophagiaErythema of the mucosa Patchy pseudomembranes or 
ulcerations Confluent pseudomembranes 
or ulcerations OR Mucosal 
bleeding with minor traumaTissue necrosis OR Diffuse 
spontaneous mucosal bleeding 
OR Life -threatening 
consequences (e .g., aspiration, 
choking)
Nausea Transient ( 24hours) or 
intermittent nausea with no 
or minimal interference with 
oral intakePersistent nausea resulting in 
decreased oral intake for 24 –48 
hoursPersistent nausea resulting in 
minimal oral intake for  48 
hours OR Aggressive 
rehydration indicated (eg, 
IVfluids)Life-threatening consequences 
(e.g., hypotensive shock)
Pancreatitis NA Symptomatic AND 
Hospitalization not i ndicated 
(other than ER visit)Symptomatic AND 
Hospitalization indicated 
(other than ER visit)Life-threatening consequences 
(e.g., sepsis, circulatory 
failure, hemorrhage)
Proctitis (functional -
symptomatic)
Also see Mucositis/ 
Stomatitis for Clinical 
ExamRectal discomfort AND No 
intervention indicatedSymptoms causing greater than 
minimal interference with usual 
social & functional activities OR 
Medical intervention indicated Symptoms causing inability to 
perform usual social/ 
functional activities O R 
Operative intervention 
indicated Life-threatening consequences 
(e.g., perforation)
Vom iting Transient or intermittent 
vomiting with no or 
minimal interference with 
oral intakeFrequent episodes of vomiting 
with no or mild dehydrationPersistent vomiting resulting 
in orthostatic hypotension OR 
Aggressive rehydration 
indicatedLife-threatening consequences 
(e.g., hypotensive shock)
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 99 02March 2017NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Alteration in Personality -
Behavior or in Mood (e.g. , 
agitation, anxiety, 
depression, mania, 
psychosis)Alteration causing no or 
minimal interference with 
usual social & functional 
activitiesAlteration causing greater than 
minimal interference with 
usual social & functional 
activitiesAlteration causing inability to 
perform usual social & 
functional activitiesBehavior potentially harmful 
to self or others (e .g., 
suicidal/homicidal ideation or 
attempt, acute psychosis) OR 
Causing inability to perform 
basic self -care functions
Altered Mental Status 
For Dementia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including 
dementia and ADD)Changes causing no or 
minimal interference with 
usual social & functional 
activitiesMild lethargy or somnolence 
causing greater than minimal 
interference with usual social 
& functional activitiesConfusion, memory 
impairm ent, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activitiesDelirium OR obtundation, OR 
coma
Ataxia Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no 
or minimal interference with 
usual social & functional 
activitiesSymptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activitiesSymptomatic ataxia causing 
inability to perform usual 
social & functional activitiesDisab ling ataxia causing 
inability to perform basic self -
care functions
Cognitive and 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention 
Deficit Disorder) Disability causing no or 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources not indicatedDisability causing greater than 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources on part -time basis 
indicatedDisability causing inability to 
perform usual social & 
functional activities OR 
Specialized resources on a 
full-time basis indicatedDisability causing inability to 
perform basic self -care 
functions OR 
Institutionalization indicated
CNS Ischemia
(acute)NA NA Transient ischemic attack Cerebral vascular accident
(CVA, stroke) with 
neurological deficit
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 100 02March 2017NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Developmental delay –
Pediatric 16 YearsMild developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate 
for the settingModerate developmental 
delay, either motor or 
cognitive, as determined by 
comparison with a 
developmental screening tool 
appropriate for the settingSevere developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the settingDevelopmental regression, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting
Headache Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference with 
usual social & functional 
activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesSymptoms causing inability to 
perform basic self -care 
functions OR Hospitaliz ation 
indicated (other than ER visit) 
OR Headache with significant 
impairm ent of alertness or 
other neurologic function
Insomnia NA Difficulty sleeping causing 
greater than minimal 
interference with usual 
social/functional activitiesDifficulty sleeping causing 
inability to perform usual 
social & functional activitiesDisabling insomnia causing 
inability to perform basic self -
care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy) Asymptomatic with 
decreased strength on exam 
OR Minimal muscle weak -
ness causing no or minimal 
interference with usual 
social & functional activitiesMuscle weakness causing 
greater than minimal 
interference with usual social 
& functional activitiesMuscle weakness causing 
inability to perform usual 
social & functional activitiesDisabling muscle weakness 
causing inability to perform 
basic self -care functions OR 
Respiratory muscle weakness 
impairing ventilation
Neurosensory Alteration 
(including paresthesia and 
painful neuropathy)Asymptomatic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social & 
functional activitiesSensory alteration or 
paresthesia causing greater 
than minimal interference with 
usual social & functional 
activitiesSensory alteration or
paresthesia causing inability to 
perform usual social & 
functional activitiesDisabling sensory alteration or 
paresthesia causing inability to 
perform basic self -care 
functions
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 101 02March 2017NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Seizure: (new onset) NA 1 seizure 2–4 seizures Seizures of any kind that are
prolonged, repetitive (e.g. , 
status epilepticus), or difficult 
to control (e .g., refractory 
epilepsy)
Seizure: (pre- existing) 
For Worsening of Existing 
Epilepsy the Grades Should 
Be Based on an Increase 
from Previous Level of 
Control to Any of These 
LevelsNA Increased frequency of pre-
existing seizures (non -
repetitive) without change in 
seizure character OR 
infrequent breakthrough 
seizures while on stable meds 
in a previously controlled 
seizure disorderChange in seizure character 
from baseline eithe r in 
duration or quality (e .g., 
severity or focality)Seizures of any kind that are 
prolonged, repetitive (e.g. , 
status epilepticus), or difficult 
to control (e .g., refractory 
epilepsy)
Seizure 
–Pediatric 18 YearsSeizure, generalized onset 
with or without secondary 
generalization, lasting 
< 5minutes with < 24hours 
post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 5 –20 
minutes with 
< 24 hours post ictal stateSeizure, generalized onset 
with or without se condary  
generalization, lasting 
> 20 minutesSeizure, generalized onset 
with or without secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated 
with a procedure)NA Present NA NA
Vertigo Vertigo causing no or 
minimal interference with 
usual social & functional 
activitiesVertigo causing greater than 
minimal interference with 
usual social & functional 
activitiesVertigo causing inability to 
perform usual social & 
functional activitiesDisabling vertigo causing 
inability to perform basic self -
care functions
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 102 02March 2017MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia
See also ArthritisJoint pain causing no or 
minimal interference with 
usual social & functional 
activitiesJoint pain causing greater than 
minimal interference with usual 
social & functional activitiesJoint pain causing inability 
to perform usual social & 
functional activitiesDisabling joint pain causing 
inability to perform basic self -
care functions
Arthritis
See also ArthralgiaStiffness or joint sw elling 
causing no or minimal 
interference with usual 
social & functional activitiesStiffness or joint sw elling causing 
greater than minimal interference 
with usual social & functional 
activitiesStiffness or joint sw elling 
causing inability to per form 
usual social & functional 
activitiesDisabling joint stiffness or 
swelling causing inability to 
perform basic self -care 
functions
Bone Mineral Loss BMD t -score or z- score
–2.5 to –1.0BMD t -score or z- score –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences
Pediatric 21Years BMD z -score 
–2.5 to –1.0BMD z -score < –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences
Myalgia
(non-injection site)Muscle pain causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle pain causing greater than 
minimal interference with usual 
social & functional activitiesMuscle pain causing 
inability to perform usual 
social & functional activitiesDisabling muscle pain causing 
inability to perform basic self -
care functions
Osteonecrosis NA Asymptomatic with radiographic 
findings AND No operative 
intervention indicatedSymptomatic bone pain with 
radiographic findings OR 
Operative intervention 
indicatedDisabling bone pain with 
radiographic findings causing 
inability to perform basic self -
care functions
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 103 02March 2017SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Acute Systemic Allergic 
Reaction Localized urticaria 
(wheals) with no medical 
intervention indicatedLocalized urticaria with medical 
intervention indicated OR Mild 
angioedema with no medical 
intervention indicatedGeneralized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasmAcute anaphylaxis OR Life -
threatening bronchospasm OR 
laryngeal edema
Chills Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesNA
Fatigue
MalaiseSymptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesIncapacitating fatigue/malaise 
symptoms causing inability to 
perform basic self -care 
functions
Fever (nonaxillary) 37.7C to 38.6C
99.8F to 101.5 F38.7C to 39.3 C
101.6 F to 102.8 F39.4C to 40.5 C
102.9 F to 104.9 F40.5C
104.9 F
Pain-Indicate Body Site
See also Injection Site 
Pain, Headache, 
Arthralgia, and MyalgiaPain causing no or 
minimal interference with 
usual social & functional 
activitiesPain causing greater than minimal 
interference with usual social & 
functional activitiesPain causing inability to 
perform usual social & 
functional activitiesDisabling pain causing 
inability to perform basic self -
care func tions OR 
Hospitalization (other than ER 
visit) indicated
Unintentional Weight 
LossNA 5% to 9% loss in body weight from 
baseline10% to 19% loss in body 
weight from baseline20% loss in body weight 
from baseline OR  Aggressive 
intervention indicated [eg, 
tube feeding or total parenteral 
nutrition]
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 104 02March 2017INJECTION SITE REACTION
Grade 1 Grade 2 Grade 3 Grade 4
Injection Site Pain (pain 
without touching)
Or Tenderness (pain when 
area is touched) Pain/tenderness causing no 
or minimal limitation of use 
of limbPain/tenderness limiting use of 
limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activitiesPain/tenderness causing 
inability to perform usual 
social & functional activitiesPain/tenderness causing inability 
to perform basic self -care 
function OR Hospitalization 
(other than ER visit) indicated 
for management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15YearsErythema OR Induration
of 55cm to 9 9cm (or 
2581 cm2)Erythema OR Induration OR 
Edema 9cm any diameter 
(or 81cm2)Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR DrainageNecrosis (involving dermis and 
deeper tissue)
Pediatric 15Years Erythema OR Induration 
OR Edema present but 
2.5cm diameterErythema OR Induration OR 
Edema > 2.5cm diam eter but 
<50% surface area of the 
extremity segment (eg, upper 
arm/thigh)Erythema OR Induration 
OR Edema involving 50% 
surface area of the extremity 
segment (eg, upper 
arm/thigh) OR Ulcerat ion 
OR Secondary infection OR 
Phlebitis OR Sterile abscess 
OR DrainageNecrosis (involving dermis and 
deeper tissue)
Pruritis Associated with 
Injection 
See also Skin: Pruritis 
(itching —no skin lesions)Itching localized to injection 
site AND Relieved 
spontaneously or w ith 
48h treatmentItching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48h treatmentGeneralized itching causing 
inability to perform usual 
social & functional activitiesNA
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 105 02March 2017ENDOCRINE/METABOLIC
Grade 1 Grade 2 Grade 3 Grade 4
Lipodystrophy (eg, back 
of neck, breasts, 
abdomen)Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious 
changes on casual visual 
inspectionNA
Diabetes Mellitus NA New  onset without need to initiate 
medication OR Modification of 
current meds to regain glucose 
controlNew  onset with initiation of 
indicated med OR Diabetes 
uncontrolled despite treatment 
modificationLife-threatening consequences 
(eg, ketoacidosis, 
hyperosmolar non -ketotic 
coma)
Gynecomastia Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious on 
casual visual inspectionNA
Hyperthyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid suppression therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modificationLife-threatening consequences 
(eg, thyroid storm)
Hypothyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid replacement therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modificationLife-threatening consequences 
(eg, myxedema coma)
Lipoatrophy (eg, fat loss 
from the face, extremities, 
buttocks)Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious on 
casual visual inspectionNA
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 106 02March 2017GENITOURINARY
Grade 1 Grade 2 Grade 3 Grade 4
Intermenstrual Bleeding 
(IMB)Spotting observed by participant 
OR Minimal blood observed 
during clinical or colposcopic 
examIntermenstrual bleeding not 
greater in duration or amount 
than usual menstrual cycleIntermenstrual bleeding greater 
in duration or amount than usual 
menstrual cycleHem orrhage with life -
threatening hypotension OR 
Operative intervention 
indicated
Urinary Tract 
obstruction (eg, stone)NA Signs or symptoms of urinary 
tract obstruction without 
hydronephrosis or renal 
dysfunctionSigns or symptoms of urinary 
tract obstruction with 
hydronephrosis or renal 
dysfunctionObstruction causing life -
threatening consequences
INFECTION
Grade 1 Grade 2 Grade 3 Grade 4
Infection (any other 
than HIV infection)Localized, no systemic antiμbial 
treatment indicated AND 
Symptoms causing no or 
minimal interference with usual 
social & functional activitiesSystemic antiμbial treatment 
indicated OR Symptoms 
causing greater than minimal 
interference with usual social 
& functional activitiesSystemic antiμbial treatment 
indicated AND Symptoms 
causing inability to perform 
usual social & functional 
activities OR Operative 
intervention (other than simple 
incision and drainage) indicatedLife-threatening 
consequences (e .g., septic 
shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shopping, cooking, use of transportation, pursuing a hobby, etc.
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 107 02March 2017Appendix 4. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)Definitions
a)Definition of Childbearing Potential
For the purposes of this study , a female born subject is considered of childbearing potential 
following 
menarche until becoming post-menopausal, unless permanentl y sterile or with 
medically  documented ovarian failure.  
Women are considered to be in a postmenopausal state when they  are > 54 y ears of age with 
cessation of previously  occurring menses for > 12 months without an alternative cause.
Permanent sterilization includes hy sterectomy , bilateral oophorectom y, or bilateral 
salpingectomy
 in a female subje ct of an y age.
b)Definition of Male Fertility
For the purposes of this study , a male born subject is considered of fertile after the initiation of 
puberty  unless permanently  sterile b y bilateral orchidectomy or medical documentation.
2)Contraception Requiremen ts for Female Subjects
a)Study Drug Effects on Pregnancy and Hormonal Contraception
The data of LDV/SOF on pregnant wome n is limited or not available. There is no suspicion of 
human teratogenicit y based on class e ffects or genotoxic potential. Relevant non c linical 
reproductive toxicity  studies for human pregnancy  do not indicate a strong suspicion of huma n 
teratogenicit y/fetotoxicity . Data from clinical pharmacokinetic interaction studies of L DV/SOF 
have demonstrated that there is no reduction in the clinica l efficacy  of hormonal contraception or 
that the effect on hormonal contraception is insignificant. Please refer to the latest version of the 
investigator’s brochure for additional information.
b)Contraception Requirements for Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires the use of highl y effective 
contraceptive measures. They  must have a negative serum pregnancy  test at Screening and a 
negative pregnancy  test on the Baseline/Day  1 visit prior t o enrollment . Thereafter, a pregnancy  
test will be performed every  4 weeks through the postt reatment Week 4 visit. Female subjects 
must also agree to one of the following from Screening until 30 day s of the last dose of 
LDV/SOF
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 108 02March 2017Complete abstinence from int ercourse of reproductive potential. Abstinence is an acceptable 
method of contraception only  when it is in line with the subject’s preferred and usual 
lifesty le. 
Or
Consistent and correct use of 1 of the following methods of birth control listed below , in
addition to a male partner who correctl y uses a condom from the date of Screening until 
30days after the last dose of LDV/SOF. 
Intrauterine device (IUD) 
Intrauterine hormone -releasing s ystem (IUS) 
Bilateral t ubal sterilization
Essure®micro -insert s ystem
Vasectom y in the male partner 
Barrier methods
■Female barriers: Diaphragm with spermicide or cervical cap with spermicide
Hormonal methods
■Oral contraceptives (either combined or progesterone only )
■Injectable progesterone
■Implants of levonorgestrel or etonorgestrel
■Transdermal contraceptive patch
■Contraceptive vaginal ring
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and until at least 30 day s after the end of relevant sy stemic exposure.
3)Contraception R equirements for Male Subjects
During the study , male subjects with female partners of childbearing potential should use 
condoms until 30 day s after the last dose of LDV/SOF treatment when engaging in intercourse of 
reproductive potential. If their female partner is of childbearing potential (as defined above), 
their female partner must use 1 of the methods of birth control listed above from the date of 
Screening until 30 day safter the last dose of LDV/SOF.
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 109 02March 20174) Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (e.g., calendar, 
ovulation, sy mptothermal, post -ovulation methods), withdrawal (coitus interruptus), spermicides 
only, and lactational amenorrhea method (LAM). Female condom and male condom should not 
be used together.
5) Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
thestudy , or if they  become pregnant within 30 day s of last dose of LDV/SOF . Subjects who 
become pregnant or who suspect that they  are pregnant during the stud y must report the 
information to the investigator and discontinue study  drug immediatel y. Subjects whose partner 
has become pregnant or suspects she is pregnant during the stud y must report the information to 
the investigator.  Instructions for reporting pregnancy , partner pregnancy , and pregnancy  
outcome are outlined in Section 7.5.2.1.
LDV/SOF
Protocol GS -US-337-4063 Final
Gilead Sciences, Inc. Amendment 3.0
CONFIDENTIAL Page 110 02March 2017Appendix 5. Opportunistic Infections
Non-
inclusive list of opportunistic infections base on AIDS-Indicator Conditions from CDC 
Classification Sy stem for HIV Infection Clinical Category  C:
Bacterial pneumonia, recurrent (two or more episodes in 12 months)
Candidiasis of the bronchi, trachea, or lungs
Candidiasis, esophageal
Cervical carcinoma, invasive, confirmed b y biopsy
Coccidioidomy cosis, disseminated or extrapulmonary
Cryptococcosis, extrapulmonary
Cryptosporidiosis, chronic intestinal (>1 month in duration)
Cytomegalovirus disease (other than liver, spleen, or nodes)
Encephalopath y, HIV-related
Herpes simplex: chronic ulcers (>1 month in duration), or bronchitis, pneumonitis, or 
esophagitis
Histoplasmosis, disseminated or extrapulmonary
Isosporiasis, chronic intestinal (>1 -month in duration)
Kaposi sarcoma
Lym phoma, Burkitt, immunoblastic, or primary  central nervous s ystem
Mycobacterium avium complex (MAC) or Mycobacterium kansasii , disseminated or 
extrapulmonary
Mycobacterium tuberculosis , pulmonary  or extrapulmonary  
Mycobacterium , other species or unidentified species, disseminated or extrapulmonary
Pneumocystis jiroveci (formerl y carinii ) pneumonia (PCP)
Progressive multifocal leukoencephalopath y (PML)
Salmonella septicemia, recurrent (nont yphoid)
Toxoplasmosis of brain
Wasting sy ndrome caused by  HIV (involuntary  weight loss >10% of baseline body  weight) 
associated with either chronic diarrhea (two or more loose stools per day  for ≥1 month) or 
chronic weakness and documented fever for 
≥1 month